Galecto Biotech AB Page 1of 105
GALACTIC -1 v7.1_UK 28 January 2022
Galecto Biotech AB 
STUDY PROTOCOL
GALACTIC -1 -A randomized, double -blind, multicentre , parallel, placebo -controlled 
Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the 
efficacy and safety of GB0139, an inhaled galectin -3 inhibitor administered via a dry 
powder inhaler over 52 weeks
Sponsor: Galecto Biote ch AB, Ole Maaloes Vej 3, DK -2200 Copenhagen, 
Denmark
Study Number: GALACTIC -1
IND Number: 124075 EudraCT Number: 2018-002664-73
Compound:
Authors:GB0139
Jie Wang, Bertil E. Lindmark, De Phung , 
Rob Slack, Catherine 
McClinton, Alison MacKinnon, Lise Gravelle, Bill Russell, Agusta 
Gudjonsdottir ,Hans Schambye
Version:
Date:7.1_UK
28 January 2022
CONFIDENTIAL PROPERTY OF GALECTO BIOTECH AB
This document is a confidential communication of Galecto Biotech AB. Acceptance of this document 
constitutes the agreement by the recipient that no information contained herein will be published or disclosed 
without written authorization from Galecto Biote ch AB except to the extent necessary to obtain informed 
consent from those persons to whom the drug may be administered. Furthermore, the information is only meant 
for review and compliance by the recipient, his or her staff, and applicable institutional r eview committee and 
regulatory agencies to enable conduct of the study.
Galecto Biotech AB Page 2 of 105
GALACTIC -1 v7.1_UK 28 January 2022
1.0 ADMINISTRATIVE 
Contacts 
A separate contact information list will be provided to each site.
Contact Type/RoleEurope
ContactUSA
Contact
Serious adverse 
event and pregnancy 
reportingSee Section 11.0 See Section 11.0
Medical Monitor DrKarina Avakova, MD, PhD
Moscow, RUSSIADr Peter G. Polos,
MD, PhD, FCCP, FAASM
301 College Road East Princeton, New 
Jersey, USA 08540
Responsible Medical 
Officer Prof. Bertil E. Lindmark MD, 
PhD
Chief Medical Officer
Galecto Biotech AB,
Ole Maaloes Vej 3,
DK-2200 Copenhagen
DenmarkProf. Bertil E. Lindmark MD, PhD
Chief Medical Officer
Galecto Biotech AB,
Ole Maaloes Vej 3,
DK-2200 Copenhagen
Denmark1.1
28 January 2022
Galecto Biotech AB Page 4of 105
GALACTIC -1 v7.1_UK 28 January 2022
INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, package insert, and any other 
product information provided by the sponsor. I agree to conduct this study in accordance with 
the requirements of this protocol and also t o protect the rights, safety, privacy, and well -being 
of study subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Practice: Co nsolidated 
Guideline.
All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations.
Regulatory requirements for reporting serious adverse events defined in Section 11.2 of 
this protocol.
Terms outlined in the Clinical Study Site Agreement.
Responsibilities of the Investigator (A).
Signature of Investigator Date
Investigator Name (print or type)
Investigator’s Title
Location of Facility (City, State/Provence)
Location of Facility (Country)
Galecto Biotech AB Page 5 of 105
GALACTIC -1 v7.1_UK 28 January 2022
TABLE OF CONTENTS
1.0 ADMINISTRATIVE ............................................................................................ 2
Contacts ..........................................................................................................2
Approval .........................................................................................................3
2.0 PROTOCOL SUMMARY .................................................................................. 10
Study Synopsis ............................................................................................. 10
Study Time and Events Schedule .................................................................. 15
3.0 STUDY REFERENCE INFORMATION ........................................................... 17
Study -Related Responsibilities ...................................................................... 17
Principal Investigator/Principal Coordinator ................................................. 17
List of Abbreviations .................................................................................... 18
4.0 INTRODUCTION .............................................................................................. 20
Study Background ........................................................................................ 20
Study Rationale ............................................................................................ 21
4.2.1 Role of Galectin -3 in fibrosis .................................................................. 21
5.0 STUDY OBJECTIVES ...................................................................................... 23
Primary Objective ......................................................................................... 23
Secondary Objective ..................................................................................... 23
6.0 STUDY DESIGN ............................................................................................... 24
Overall design ............................................................................................... 24
Number of Participants ................................................................................. 25
Participant -and Study completion ................................................................ 25
Study Design Rationale ................................................................................. 25
Dose Justification ......................................................................................... 27
Dosing .......................................................................................................... 27
7.0 STUDY POPULATION ..................................................................................... 27
Inclusion Criteria .......................................................................................... 27
Exclusion Criteria ......................................................................................... 28
8.0 STUDY DRUG .................................................................................................. 31
Study Drug Administration ........................................................................... 31
Permitted medications ................................................................................... 32
Proh ibited Medications including approved and non -approved medications for 
IPF................................................................................................................ 32
8.3.1 Medications approved for IPF ................................................................ .32
8.3.2 Non-approved medications for IPF .......................................................... 321.2
2.1
2.2
3.1
3.2
3.3
4.1
4.2
5.1
5.2
6.1
6.2
6.3
6.4
6.5
6.6
7.1
7.2
8.1
8.2
8.3
Galecto Biotech AB Page 6 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Management of Clinical Events .................................................................... 33
Blinding and Unblinding procedures ............................................................. 33
8.5.1 Blinding .................................................................................................. 33
8.5.2 Unblinding .............................................................................................. 33
Description of Investigational Agents ........................................................... 34
Packaging and Labeling ................................................................................ 34
Storage, Handling, and Accountability .......................................................... 35
9.0 STUDY END POINTS ....................................................................................... 36
Primary Endpoint .......................................................................................... 36
Key Secondary Endpoints ............................................................................. 36
Secondary endpoints ..................................................................................... 36
Safety Endpoints ........................................................................................... 37
Exploratory Endpoints .................................................................................. 37
9.5.1 Biomarkers ............................................................................................. 37
9.5.2 Initiation or termination of nintedanib and pirfenidone in the previous 
stratified study population ....................................................................... 37
9.5.3 Time to initiation of pirfenidone or nintedanib treatment for SoC2 
participants up to the time when SoC1 and SoC2 were remov ed in the 
study.Pharmacogenetics .......................................................................... 37
10.0 STUDY CONDUCT ........................................................................................... 38
Study Personnel and Organizations ............................................................... 38
Arrangements for Recruitment of Subjects .................................................... 38
Visit schedule ............................................................................................... 38
10.3.1 Screening & Randomisation .................................................................... 38
10.3.2 Re-screening visit .................................................................................... 39
10.3.3 Treatment period ..................................................................................... 39
10.3.4 Study treatment completion and Follow -up period .................................. 40
Study procedures .......................................................................................... 40
10.4.1 Data collection ........................................................................................ 40
10.4.2 Informed Consent .................................................................................... 41
10.4.3 Subject Demographics ............................................................................ 41
10.4.4 Medical History ...................................................................................... 41
10.4.5 Physical Examination .............................................................................. 42
10.4.6 Vital Signs .............................................................................................. 42
10.4.7 Health -related Quality of Life Questionnaires ......................................... 42
10.4.8 12-Lead Electrocardiogram ..................................................................... 438.4
8.5
8.6
8.7
8.8
9.1
9.2
9.3
9.4
9.5
10.1
10.2
10.3
10.4
Galecto Biotech AB Page 7 of 105
GALACTIC -1 v7.1_UK 28 January 2022
10.4.9 Clinical Laboratory Evaluations .............................................................. 43
10.4.10 Pregnancy Test .................................................................................. 44
10.4.11 Biomarkers ........................................................................................ 44
10.4.12 Geneti cs Sample ................................................................................ 45
10.4.13 Spirometry ........................................................................................ 45
10.4.14 Pulse Oximetry.................................................................................. 45
10.4.15 DLCO ............................................................................................... 45
10.4.16 6MWT .............................................................................................. 45
10.4.17 HRCT central overread ...................................................................... 45
10.4.18 Concomitant Medications and Procedures ......................................... 46
10.4.19 Adverse Events ................................................................................. 46
Disco ntinuation of study treatment ................................................................ 46
Withdrawal of Subjects from the Study ......................................................... 46
Study Compliance ......................................................................................... 47
11.0 ADVERSE EVENTS ......................................................................................... 48
Definitions .................................................................................................... 48
11.1.1 Pretreatment Event Definition ................................................................ .48
11.1.2 Treatment Emergent Adverse Event ........................................................ 48
11.1.3 Adverse Event Definition ........................................................................ 48
11.1.4 Serious Adverse Event Definition ........................................................... 48
Procedures for Recording and Reporting Adverse Events and Serious 
Adverse Events ............................................................................................. 50
11.2.1 SAE Reporting Contact Information: ...................................................... 51
Monitoring of Adverse Events and Period of Observation ............................. 52
Procedures for Reporting Drug Exposure During Pregnancy and Birth Events
.................................................................................................................... 52
Procedures for Reporting Product Complaints or Medication Errors (Including 
Overdose) ..................................................................................................... 53
Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 53
12.0 SAFETY MONITORING ................................................................................... 54
Data and Safety Monitoring Board (DSMB) ................................................. 54
Event Adjudication ....................................................................................... 54
13.0 DATA HANDLING AND RECORD KEEPING ................................................ 55
eCRFs ........................................................................................................... 55
Record Retention .......................................................................................... 56
14.0 STATISTICAL METHODS ............................................................................... 5710.5
10.6
10.7
11.2
11.6
12.1
12.2
13.1
13.2
Galecto Biotech AB Page 8 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Statistical and Analytical Plans ..................................................................... 57
Statistical Hypothesis .................................................................................... 57
14.2.1 Primary efficacy endpoints ...................................................................... 58
14.2.2 Key Secondary Efficacy Endpoints: ........................................................ 58
Analysis Sets ................................................................................................ 58
Primary Efficacy Analysis ............................................................................ 59
14.4.1 Analysis of Primary Efficacy Endpoint ................................................... 59
14.4.2 Analysis of Secondary Endpoints ............................................................ 60
Secondary Efficacy Analysis ......................................................................... 62
14.5.1 Other Analyses ........................................................................................ 62
14.5.2 Safety Analysis ....................................................................................... 62
Determination of Sample Size ....................................................................... 64
Randomization .............................................................................................. 64
Handling of Missing Data ............................................................................. 64
15.0 QUALITY CONTROL AND QUALITY ASSURANCE .................................... 67
Study -Site Monitoring Visits ........................................................................ 67
Protocol Deviations ....................................................................................... 67
Quality Assurance Audits and Regulatory Agency Inspections ..................... 68
16.0 ETHICAL ASPECTS OF THE STUDY ............................................................. 69
IRB and/or IEC Approval ............................................................................. 69
Subject Information, Informed Consent, and Subject Authorization .............. 70
Subject Confidentiality ................................................................................. 72
Publication, Disclosure, and Clinical Trial Registration Policy ...................... 72
16.4.1 Publication .............................................................................................. 72
16.4.2 Clinical Trial Regist ration ....................................................................... 73
16.4.3 Clinical Trial Results Disclosure ............................................................. 73
Insurance and Compensation for Injury ......................................................... 73
17.0 REFERENCES ................................................................................................... 75
18.0 APPENDICES .................................................................................................... 79
Appendix 1. Plastiape DPI Inhaler Device - Instructions for Use ................... 79
Appendix 2. Biomarker Panel ....................................................................... 83
Appen dix 3. Definition of Acute Exacerbations in IPF .................................. 94
19.0 A. RESPONSIBILITIES OF THE INVESTIGATOR ....................................... 10414.1
14.2
14.3
14.4
14.5
14.6
14.7
14.8
15.1
15.2
15.3
16.1
16.2
16.3
16.4
16.5
18.1
18.2
18.3
Galecto Biotech AB Page 9of 105
GALACTIC -1 v7.1_UK 28 January 2022
LIST OF TABLES
Table 1: Study Time & Events Schedule ............................................................... 15
Table 2: Clinical Chemistry and Hematology Tests ............................................... 43
Table 3: Clinical Urinalysis Tests ......................................................................... 43
Table 4: Biomarker Panel ..................................................................................... 45
Table 5: Handling of anticipated ICEs for treatment effect of primary endpoint ....65
LIST OF FIGURES
Figure 1: Study Schematic Diagram ....................................................................... 24
Galecto Biotech AB Page 10 of 105
GALACTIC -1 v7.1_UK 28 January 2022
2.0 PROTOCOL SUMMARY
Study Synopsis
Name of Sponsor(s):
Galecto Biotech ABCompound:
GB0139 (previous lyknown as TD139)
Title of Protocol: 
GALACTIC -1 -A randomized, double -blind, 
multicentre, parallel, placebo -controlled phase 2b 
study in subjects with idiopathic pulmonary fibrosis 
(IPF) investigating the efficacy and safety of GB0139 , 
an inhaled galectin -3 inhibitor administered via a dry 
powder inhaler over 52 weeksIND No.: 124075 EudraCT No.: 
2018-002664 -73
Study Number: GALACTIC -1 Phase: IIb
Co-ordinating Investigator Toby Maher MD MSc PhD FRCP
Professor of Medicine and Director of Interstitial Lung 
Disease.
Keck School of Medicine of USC
University of Southern California
Department of Medicine
Division of Pulmonary, Critical Care and Sleep 
Medicine
2020 Zonal Avenue, IRD 724
Los Angeles, CA 90033
Overview (Figure 1)
Population: 
All subjects enrolled into the study will have a diagnosis of IPF established within the previous five years, and a 
diagnostic HRCT scan assessed according the ATS/ERS/Fleischne r criteria available within the previous 12 
months (up to 12 months +27 days ). 
Treatment:
All subjects eligible for the study will be randomised in a 2:1 ratio to one of two treatment arms:
A.GB0139 3mg once a day (2x 1.5mg capsules) by inhalation 
B.Placebo once a day (2x placebo capsules) by inhalation
The stratification at randomization and the following SoCs are removed in Protocol version 6. 1_UK such that 
all future participants will not be treated with nintedanib or pirfenidone at screening and ranodmisation:
The two strata of Standard of Care (SoC) were as follows in the previous study design:
1.SoC1 : Subjects currently on treatment with either pirfenidone or nintedanib. 
2.SoC2: Subjects not currently treated with pirfenidone or nintedanib.2.1
Galecto Biotech AB Page 11of 105
GALACTIC -1 v7.1_UK 28 January 2022
Evaluation and follow up:
From baseline to week 52, visits will be scheduled at weeks 0, 4, 8, 12, 26, 40 and 52 for evaluations according 
to the Time & Events Table (Section 2.2). A subject’s follow -up safety assessment will be performed via a 
phone call one week after the last study visit .
Number of Subjects
Estimated to randomize approximately 141participants in total 
Dose Level(s)
•GB0139 3mg once a day (2x 1.5mg capsules) by inhalation 
•Placebo once a day (2x placebo capsules) by inhalation
Duration of Treatment & Follow up
•52-weeks treatment after randomisation
•Follow up via a phone call one week after 
the last study visit
Main Criteria for Inclusion
1.Male and female subjects aged ≥ 40 years of age with a diagnosis of IPF established during the previous 
five years according to ATS/ERS/Fleischner cr iteria. A historical diagnostic HRCT scan assessed according 
to the ATS/ERS/Fleischner criteria must be available from within the 12 months (up to 12 months +27 
days) prior to screening. Diagnostic HRCTs will be subject to central reading for confirmation.
2.Lung function parameters as follows:
a.FVC > 45% of the predicted value at screening
b.DLCO (corrected for Hb) of 30% to 79% of the predicted value at screening.
3.Patients who currently are not being treated with nintedanib or pirfenidone ; or cannot tolerate nintedanib or 
pirfenidone .
4.Subjects must sign and date a written, IRB/EC approved informed consent form and any required 
authorization prior to initiation of any study procedures.
Main Criteria for Exclusion
Subjects meeting any of the following exclusion criteria are not to be enrolled in the study/randomized to 
treatment:
1.Currently has significant airways obstruction: FEV1/FVC ratio of < 0.7 at screening .
2.Has clinical evidence of active infection, including, but not limited to, bro nchitis, pneumonia, sinusitis, 
urinary tract infection, and cellulitis.
3.Has a history of malignancy within the last 2 years with the exception of basal cell carcinoma, 
squamous cell carcinoma of the skin (localised, treated or cured), chronic lymphocytic l eukaemia 
(under observation) and prostate cancer requiring anti -androgens, localised treatment (minor surgery, 
radiotherapy) and/or managed by observation.
4.Has any condition other than IPF that, in the opinion of the investigator, is likely to result in th e death 
of the subject within the next 2 years.
Galecto Biotech AB Page 12of 105
GALACTIC -1 v7.1_UK 28 January 2022
5.Presence of other disease that may interfere with testing procedures or in the judgement of the 
Investigator may interfere with trial participation or may put the patient at risk when participating in 
this tr ial.
6.Is likely to receive lung transplantation within the next 12 months.
7.Currently receiving nintedanib, pirfenidone, high dose corticosteroid, cytotoxic (e.g., chlorambucil, 
azathioprine, cyclophosphamide, methotrexate), vasodilator therapy for pulmonary hypertension (e.g., 
bosentan). Also see prohibited medications (Section 8.3.2 ). A current dose of less than or equal to 15 
mg/day of prednisone or its equivalent is acceptable if the dose is anticipated to remain stable during 
the study. 
8.Prior use of GB0139 or previously randomised in GALACTIC -1. 
9.Prior use of nintedanib or pirfen idone within 7 days of initiation of screening.
10.Prior use of investigational drugs within 30 days (or 5 half-lives, whichever is longer) of initiation of 
screening.
11.Participating in another interventional clinical trial. 
12.Has a history of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the 
previous six months, including, but not limited to, the following:
a.Unstable angina pectoris or myocardial infarction, or percutaneous coronary intervention 
within the last 6 months
b.Congestive heart failure requiring hospitalization 
c.Uncontrolled clinically significant arrhythmias. 
13.If female, the subject is pregnant or lactating or intending to become pregnant before participating in 
this study during the study and within 33days after l ast dose of the study drug; or intending to donate 
ova during such time period. 
14.Woman considered to be of childbearing potential who do not use highly effective birth control 
methods during the study and for 33 days after last administration of study drug . 
15.Male partners of women of child bearing potential not committing to using condoms during the course 
of the study and 90 days after last administration of study drug, unless they have undergone male 
sterilization. 
16.Hypersensitivity to the active substanc e (GB0139 ) or the excipient (lactose ).
Study Objectives
Primary Objectives
Evaluate the effect of GB0139 dry powder for inhalation compared with placebo over 52 weeks 
treatment period on the annual rate of decline in FVC in participants with IPF who are not treated with 
or cannot tolerate nintedanib or pirfenidone .
Secondary Objectives
Further characterize t he effect of GB0139 compared with placebo over 52 weeks treatment period on 
FVC, also on the quality of life, time to respiratory -related hospitalizations and all -cause mortality.
Galecto Biotech AB Page 13of 105
GALACTIC -1 v7.1_UK 28 January 2022
Main Criteria for Evaluation and Analyses
Primary Endpoint
•The annual rate of decline in Forced Vital Capacity (FVC; expressed in mL over 52 weeks) 
Key Secondary Endpoints
•Proportion of subjects with an absolute decline from baseline in FVC % pred of ≤10% at w52.
•Change from baseline in St. George’s Respiratory Ques tionnaire (SG RQ) total score at w52.
•Time to first hospitalization (respiratory related, including acute exacerbation of IPF).
•Time to death (all -causes).
Additional secondary and exploratory efficacy variables with bearing on the efficacy of GB0139 (e.g., other 
QoL) are described in detail in the Main Criteria and Evaluation and Analyses below ).
Other Secondary Endpoints 
•Proportion of subjects with an abso lute decline from baseline in FVC % pred of ≤5% at w52
•Change from baseline in 6-minute walk test (6MWT) distance over 52 weeks
•Change in diffusion capacity of the lung for carbon monoxide (DLCO), corrected for Hb
•Change from baseline at week 52 for dyspno ea assessment by University of California San Diego -
Shortness of Breath Questionnaire (UCSD -SOBQ)
•Change from baseline at week 52 for HRQoL as assessed by Short Form Survey (SF -36) 
•Percentage of subjects with Adverse Events (AE) or Serious Adverse Eve nts (SAE)
•Time to first hospitalization (IPF related, including acute exacerbation of IPF)
•Time to first hospitalization (all cause)
•Time to respiratory related death
•Time to initatiation of nintedanib or pirfenidone
•Change in FVC expressed in mL over 52 weeks for subjects who have never been treated with 
pirfenidone or nintedanib
Exploratory Endpoints
Biomarkers : Change from baseline of selected biomarkers. These may include but are not limited to: 
YKL -40, PAI -1, PDGF -BB, MCP -1, CCL -18, Gal-3, markers of collagen metabolism .
Time to initiation of pirfenidone or nintedanib treatment for SoC2 participants up to the time when 
SoC1 and SoC2 were removed in the st udy
Pharmacogenetics : The study includes a pharmacogenetic component. This is not mandatory in order 
for a subject to participate in the study.
Statistical Considerations: 
The primary efficacy analysis will be based on the comparison between the GB0139 3 mg group against the 
Placebo group in patients who were not treatedwith nintedanib or pirfenidone at screening .
Galecto Biotech AB Page 14of 105
GALACTIC -1 v7.1_UK 28 January 2022
The primary endpoint of this trial ,annual rate of decline in FVC, will be analyzed by a random coefficient 
regression model including treatment group andbaseline FVC (mL ).
The key secondary endpoints will be analysed as follows: Proportion of participants with an absolute decline 
from baseline in FVC % predicted of ≤10% at week 52 wil l be analysed by logistic regression including 
treatment and baseline FVC (mL) in the model. 
Change from baseline in the SGRQ total score at week 52 will be analysed by a mixed model repeated measure.
The time to first hospitalization (any respiratory related) will be analysed by a Cox PH model .  
Time to death (all -causes) will be analysed by Cox PH model. 
Secondary and further endpoints will be analysed in an exploratory manner.
Sample size justification:
The annual decline in FVC for placebo is estimated to be 200ml. To detect a d ifference from placebo in the 
decline of FVC of 100ml with a standard deviation of 240ml at the signific ance level of 10%, a sample size of 
141, with a randomization ratio of 2:1, the study would have 75% power.
Galecto Biotech AB Page 15of 105
GALACTIC -1 v7.1_UK 28 January 2022
Study Time andEvents Schedule
Table 1: Study Time & Events Schedule
Visit 1 2 3 4 5 6 7 8 Withdrawal9Follow up7
Screening1Baseline Treatment
Weeks of treatment 0 4 8 12 26 40 52 -
Day
Time window                      
6 weeks029
±357
±385
±3183
±7281
±7365
±77 days after final 
study visit (+7 
days)
Informed consent X
HRCT sent to central review X
Demographics (including height, weight) X
Medical history X
Randomization X
ln-/exclusion criteria X X
Physical examination, vital signs X X X X X X X X X
HRQoL (SGRQ, SF -36) X X X X
Dyspnoea index (UCSD -SOBQ) X X X X
12-lead ECG X X X X X X X X
Laboratory test (chemistry, haemtaology)2 X X X X X X X X X
Urinalysis X X X X X X X X
Pregnancy test3, 4X X X X X X X X X
Biomarker sample X X X X X
Genetics sample5X
Spirometry (FVC, FEV1) X X X X X X X X X
SpO 2 X X
DLCO X X X
6MWT X X X
Administer 1st study medication (at clinic) & 
inhaler training6X
Dispense trial drug X X X X X X
Compliance / drug accountability7X X X X X X X
Adverse events & conc. meds8 X X X X X X X X X X
Notes:
1. HRCT confirmation by central reading must be obtained as soon as possible following screening visit 1 and prior to visit 2
2. See Table 2and Table 3Section 10.4.92.2
Galecto Biotech AB Page 16of 105
GALACTIC -1 v7.1_UK 28 January 2022
3. In women of childbearing potential only: serum b -
HCG will be required at visit 1 only, followed by urinary testing at subsequent visits.
4. This is optional and separate consent must be obtained. The sample can be taken at other study visits.
5. Sub jects should be observed for 1 hour after the first dose to monitor for any acute adverse effects of study drug administration (e.g., bronchospasm –see Section 8.1)
6.Includes checking the subject’s use of the DPI device (Plastiape monodose inhaler)
7. The follow -up will be performed via a phone call .
8. Events occurring prior to randomization and administration of drug are considered as pre -treatment (as defined in Se ction 11.1.1 ). Adverse events are also collected for up to the phone 
follow up .
9. FVC, DLCO and 6MWT will be performed as part of the withdrawal assessments.
Galecto Biotech AB Page 17 of 105
GALACTIC -1 v7.1_UK 28 January 2022
3.0 STUDY REFERENCE INFORMATION
Study -Related Responsibilities 
Syneos Health and Biorasi the CROs designated to execute the study, will perform all study-
related activities as described in this study protocol. IQVIA serves as the central vendor to 
manage SAE reporting and the study safety database.
Principal Investigator/Principal Coordinator
Galecto Biotech AB together with Syneos Health has select eda Signatory Coordinating 
Investigator from the investigators who participate in the study. Selection criteria for this 
investigator will include significant knowledge of the study protocol, the study med ication, their 
expertise in the therapeutic area and the conduct of clinical research as well as study 
participation. The Signatory Coordinating Investigator will be required to review and sign the 
clinical study report and by doing so agrees that it accur ately describes the results of the study.3.1
3.2
Galecto Biotech AB Page 18 of 105
GALACTIC -1 v7.1_UK 28 January 2022
List of Abbreviations
6MWT 6 minute walk test
ALP alkaline phosphatase
ALT
AMalanine aminotransferase
alveolar macrophages
AST
ATAaspartate aminotransferase 
American Thoracic Association
BAL
BALFbronchoalve olar lavage
bronchoalveolar lavage fluid
CHF
CHI3L1congestive heart failure 
chitinase -3-like protein 1
COPD chronic obstructive pulmonary disease
eCRF electronic case report form 
CRO contract research organization
HRCT high resolution computed tomography
DLCO diffusion lung capacity for carbon monoxide
ECG
ECM
EMAelectrocardiogram
extracellular matrix
European Medicines Agency
FEV1 forced expiratory volume in 1 s
FDA
FUV
FVC
Gal-3Food and Drug Administration 
Follow -up Visit
forced vital capacity 
galectin -3 
GCP good clinical practice
GGT -glutamyl transferase
ICH International Conference on Harmonisation
IEC
ILD
IPFindependent ethics committee
interstitial lung disease
idiopathic pulmonary fibrosis
IRB institutional review board
IVRS interactive voice response system
IWRS
NAC
KL-6interactive web response system 
N-acetylcysteine
Krebs’ von de Lungen -6
LSLV
MADlast subject last visit
multiple ascending dose 3.3
Galecto Biotech AB Page 19of 105
GALACTIC -1 v7.1_UK 28 January 2022
MoA mechanism of action
MedDRA
NOAELs
NSIPMedical Dictionary for Regulatory Activities 
no-observed -adverse -effect -levels 
non-specific interstitial pneumonia 
MRI magnetic resonance imaging
NYHA
OD
PAI-1New York Heart Association
once per day
plasminogen activator inhibitor 1
PD
PDGF
PFTprogressive disease 
platelet derived growth factor
pulmonary function test
PFS
PH
p.o.
PKprogression -
free survival 
pulmonary hypertension
per os (oral) 
pharmacokinetic
QoL
RT
RRTquality of life
retention time 
relative retention time
SAE serious adverse event 
SAD single ascending dose
SmPC summary of product characteristics 
SoC standard of care
TGF transforming growth factor β 
TLC
TIDtotal lung capacity 
three times per day
UIP usual interstitial pneumonia   
WHO
WBC
YKL -40World Health Organization  
Leukocytes (white blood cells) 
chinitnase -3-like protein 1
Galecto Biotech AB Page 20 of 105
GALACTIC -1 v7.1_UK 28 January 2022
4.0 INTRODUCTION
Study Background
Idiopathic pulmonary fibrosis (IPF), the most common form of the idiopathic interstitial 
pneumonias, is a chronic, progressive, irreversible, and usually lethal lung disease of unknown 
cause. IPF occurs mostly in elderly adults, is limited to the lungs, and is associated with a 
histopa thological or radiological pattern typical of usual interstitial pneumonia (UIP) [ 1-3]. The 
disease course is heterogeneous with clinical course highly variable from one subject to another. 
In general, the clinical course can be relatively slow but progressive or very rapid with 
deterioration leading to decline in lung function and death. The clinical picture is invariably 
characterized by worsening cough and dyspnea, respiratory insufficiency and an overall poor 
prognosis with median survival between 2 to 3 years from diagnosis [ 4-7]. 
The cause of IPF is unknown, but it appears to be a disorder likely arising from the interplay 
between environmental and genetic factors. Cigarette smo king is the most consistent 
environmental risk factor. Genetic factors have also been strongly implicated in both sporadic 
IPF and familial pulmonary fibrosis. A growing body of evidence suggests that the disease 
process is initiated through alveolar epith elial cell microinjuries and apoptosis. Subsequently, 
fibroblasts proliferate and differentiate into myofibroblasts, leading to the excessive 
accumulation of extracellular matrix (ECM) components including collagen and fibronectin 
under the control of prof ibrogenic stimuli such as transforming growth factor β (TGF -β). The 
resulting fibrotic tissue is characterized by excessive scarring, organ injury, function decline and 
organ failure [8-13].TGF- β has been assigned a clear pathogenic role by its induction of ECM 
production and apoptosis of alveolar epithelial cells (AECs) in IPF. Inhibiting TGF -β activity, in 
experimental models of lung fibrosis reduces the fibrosis. [ 14-23].
The natural history of IPF is heterogeneous; therefore, raising a number of challenges for 
individual patient management. There are a number of asymptomatic subjects with subclinical, 
undiagnosed disease, especially among the elderly [ 24, 25 ].Some subjects remain relatively 
stable for a prolonged period of time, while others progress rapidly [ 26] and some experience 4.1
Galecto Biotech AB Page 21 of 105
GALACTIC -1 v7.1_UK 28 January 2022
acute exacerbations of IPF, e.g., acute res piratory worsening [ 27] of unidentified cause [28 ] 
leading to non -elective hospitalization and frequently death [ 29]. IPF has a broad and profound 
impact on subjects’health- related quality of life (HRQoL) [ 30, 31].
Two drug therapies, pirfenidone and nintedanib , are currently licensed for the treatment of IPF. 
Both therapies are only conditionally recommended by the current official ATS/ERS/JRS/ALAT 
clinical practice guidelines for the treatment of IPF due to the potentially significant adverse 
effects with both therapie s [36].Both drugs appear to have comparable efficacy, approximately 
halving the rate of disease progression over 52 weeks as assessed by decline in FVC when 
compared with placebo. However, neither has shown clear evidence of a survival or symptomatic 
benefit [32-35].Moreover, tolerability limits the use of both drugs in some subjects, and it 
increasingly recognized that a number of subjects either r equire a reduced dose or have to stop 
treatment [ 36-39].Hence there remains a significant unmet medical need in IPF.
Although they have been widely used in the past, current evidence does n ot support the use of 
corticosteroid or immunosuppressant as a therapy for IPF [ 3, 40, 41].Indeed, long- term 
corticosteroid therapy is associated with signi ficant treatment -related morbidity and various 
potentially severe side effects. As a result, current evidence -based guidelines [ 3]provide a strong 
recommendation against the use of corticosteroid monotherapy in IPF, albeit in the absence of 
any randomized placebo- controlled trial. 
Study Rationale
4.2.1 Role of Galectin -3 in fibrosis
Gal-3 is a beta -galactoside -binding mammalian lectin (a carbohydrate binding protein) of 
approximately 30 kDa which is evolutionarily highly conserved [ 42]. In multiple models of 
organ fibrosis, it has been demonstrated that Gal -3 is potently pro- fibrotic, modulating the 
activi ty of fibroblasts and macrophages in chronically injured tissues [ 18, 43- 48].It is 
hypothesized that increased Gal -3 expression during chronic injury leads to fibroblast activation 
via the aggregation of growth factor receptor clusters (such as TGF -ß), thereby amplifying pro-4.2
Galecto Biotech AB Page 22of 105
GALACTIC -1 v7.1_UK 28 January 2022
fibrotic signal cascades. Mice that are deficient in Gal -3, although phenotypically normal, 
develop reduced fibrosis in response to tiss ue injury in lung, liver, blood vessels, heart, and 
kidney, and also in response to allograft rejection 
[43-48].In addition, preclinical studies using 
direct intratracheal administration of the galectin -3 inhibitor GB0139 showed that GB0139
decreased bleomycin -induced fibrosis when administered during the fibrotic phase in mice [ 18,
49]. Thus , Gal - 3 may be an important regulator of fibrosis, and these pre -clinical studies provide 
a proof of principal that inhibition of Gal -3 in man could be a potential novel therapeutic 
strategy. Gal -3 is up -regulated in subjects with IPF with elevated levels of Gal -3 in 
bronch oalveolar lavage fluid and serum [18] but not in non- specific interstitial pneumonia 
(NSIP), suggesting that Gal -3 may be a more specifically associated with disease pathogenesis 
and outcome in IPF. Gal -3 is also upregulate d during acute exacerbations of IPF. Gal -3 
expression is also up -regulated in other chronic fibroses, including fibrotic liver disease, 
regardless of etiology [ 44]. Together, these observations support the development of Ga l -3 
selective inhibitors for IPF.
GB0139 is a small molecule lectin inhibitor designed specifically to modulate the fibrogenic 
response to tissue injury. GB0139 has been formulated for inhaled delivery to both target the 
disease site in the periphery of the lung in IPF more directly, and to limit any potential systemic 
toxicity. More details on the profile of GB0139 be found in the Investigator’s Brochure (IB).
Galecto Biotech AB conducted a phase 1 clinical study in human volunteers and in 24 subjects 
with IPF in which GB0139 was delivered once daily by dry powder inhalation using a Plastiape 
device. The trial was divided into two parts. Part 1 (single ascending dose) explored the safety 
and tolerability of GB0139 in healthy volunteers. Part 2 (IND opening study) investigated the 
safety, tolerability pharmacokinetics and pharmacodynamics in subjects with IPF. The clinical 
protocol was discussed with the FDA during a pre -IND meeting held on 03 December 2014, and 
the changes suggested by the Agency were implem ented before Part 2 of the protocol was 
conducted under the IND.
Galecto Biotech AB Page 23 of 105
GALACTIC -1 v7.1_UK 28 January 2022
The results from clinical trial GB -HV-01 confirm that GB0139 is safe and well tolerated at 
single inhaled doses up to 50 mg in healthy volunteers [Single Ascending Dose (Part 1)], and 
multipl
e inhaled doses up to 10 mg daily in IPF subjects during 2 weeks of treatment [Multiple 
Ascending Dose (Part 2)]. Further, GB -HV-01 demonstrated that GB0139 reaches the alveolar 
macrophages at pharmacologically relevant concentrations and causes a dose -dependent 
reduction in cell surface Galectin-3 in participants with IPF . In addition, dose -response related 
reductions were observed in the plasma levels of putative IPF biomarkers (YKL -40, PAI -1, 
PDGF -BB, and CCL18 ), which have been associated with IPF disea se severity and all -cause 
mortality [ 50].
Based on both preclinical and available clinical data, GB0139 is expected to demonstrate a 
favou rable risk/benefit profile compared with existing treatment options. No dose -limiting
toxicity has been observed in preclinical testing. In addition, the inhaled route of delivery targets 
the site of the disease directly, with the potential to limit systemic side effects. 
5.0 STUDY OBJECTIVES
Primary Objective
The primary objective of the stu dy is to evaluate the effect of GB0139 dry powder for inhalation 
compared with placebo over 52 weeks treatment period on the annual rate of decline in FVC in 
participants with IPF who are not treated with or cannot tolerate nintedanib or pirfenidone. 
Seco ndary Objective
The secondary objective of the study is to further characterize the effect of GB0139 compared 
with placebo over 52 weeks treatment period on FVC, also on the quality of life, time to 
respiratory- related hospitalizations and all -cause mortality. 5.1
5.2
Galecto Biotech AB Page 24 of 105
GALACTIC -1 v7.1_UK 28 January 2022
6.0 STUDY DESIGN
Overall design
Following a review of unblinded efficacy and safety data by the study’s DSMB in Feb2021, the 
study design is modified based on the DSMB’s recommendation. DSMB has recommended the 
participants randomised to the 10 mg GB0139 group and all those currently taking nintedanib or 
pirfenidone should be discontinued from the study. Galecto expects to continue recruiting 
participants who are no ttaking nintedanib or pirfenidone at screening and who would be 
randomised to receive 3 mg GB0139 or placebo.
This remains a multicenter, randomized, double -blind, placebo -controlled trial in subjects with 
IPF. The updated design based on the above DSMB’s recommendation is summarized in Figure 
1below. 
Figure 1: S tudy Schematic Diagram
6.1
GB0139 3mg (n=113)
Placebo (n=56)
S R
i i I I
w0F
Final efficacy analysis
Rate of FVC decline
i i
w52
Screening Treatment
Up to 6 weeks 52 weeks
S — Screening R- randomizationPhone Follow Up
7 days after last visit
Galecto Biotech AB Page 25 of 105
GALACTIC -1 v7.1_UK 28 January 2022
There are three study periods:
Screening Period –After signing the study inform consent form (ICF) participant will enter a 
screening period up to 6 weeks. 
Treatment Period -Following randomization, eligible participants will receive blinded treatment, 
GB0139 or placebo, for 52 weeks. Clinic visits will be performed at week 0/baseline, and then at 
weeks 4, 8, 12, 26, 40, and 52 according to the Study Time and Events Table (Section 2.2)
Follow up P eriod -At the end of the treatment period (week 52), a safety follow -up phone call 
will be performed 7 days after the withdrawal/last study visit. 
Number of Participants
Approximately 141participants in total will be randomized in GALACTIC -1.
Participa nts are considered evaluable if they have taken at least one dose of the double -blind 
treatment. 
Participants who prematurely discontinue double -blind study treatment after randomization can 
remain in the study and complete the remaining scheduled visits, if possible.
Any participants who withdrawn from the study after randomization cannot be replace dand re -
screened. 
Participant -and Study completion
A participant is considered to have completed the study if he/she has completed all periods of the 
study including follow up visit. 
The end of study is defined as the date of the last safety follow up via phone of the last 
participant in the study. 
Study Design Rationale
Based on the DSMB’s recommendation, GALACTIC -1 can continue to randomise participants 
with IPF to receive either placebo or 3 mg GB0139 in a randomized and blinded fashion. 6.2
6.3
6.4
Galecto Biotech AB Page 26of 105
GALACTIC -1 v7.1_UK 28 January 2022
A placebo treatment arm included in the study is to allow for a quantitative assessment of the 
efficacy of 3 mg GB0139 compared with an inactive control. Use of the pla cebo is also essential 
in the evaluation of the GB0139 safety in this study. 
DSMB also recommended no further co
-administration of GB0139 with nintedanib and 
pirfenidone. Therefore, patients who are not currently taking or cannot tolerate nintedanib or 
pirfenidone will be eligible for screening (Section 7.0). Furthermore, nintedanib and pirfenidone 
are defined as study prohibited medications in Protocol version 6. 1_UK . 
Eligible participants will be randomized in a ratio of 2:1 to receive either 3 mg GB0139 or 
placebo. The updated design has maintained the ratio of active to placebo in the original study 
design, after the 10 mg GB0139 treatment group was removed in Protocol version 6. 1_UK .  
The 12 months (52 weeks) treatment duration is considered optimal for evaluating the primary 
endpoint in the study.
FVC is generally accepted as a measure of disease severity and as a predictor of survival in IPF. 
FVC is also commonly used as the primary efficacy measure for clinical trials in IPF. The 
decline of lung function in IPF is punctuated by acute exacerbations which carry a substantial 
risk of hospitalization and mortality. Thus, any intervention which reduces the time to 
exacerbation represents a substantial benefit and will be evaluated. In addition to measurements 
of lung volume (FVC), diffusion capacity for carbon monoxide (DLCO) as well as oxygen 
saturation (SpO2) will be monitored and assessed as secondary lung function endpoints.
Survival is recognised as an important measure to evaluate effect of a potential treatment for IPF 
therefore , time to death (all-cause mortality) isincluded as one of the key 
secondary endpoint s. 
Patients wi th IPF also suffer from dyspnea, cough and poor exercise tolerance, which can reduce 
the quality of life and cause a severe restriction in their activities of in every -day life. Therefore, 
a number of patient-reported outcome instruments including SGRQ will be used to document the 
effect on symptoms and their impact on the patient’s quality of life. 
Galecto Biotech AB Page 27 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Dose Justification
In the phase Ib study in IPF patients 3 mg GB0139 administered via dry powder inhaler has 
shown to reduce alveolar macrophage (AM) Gal -3 sur face expression to 42.8 % of baseline 
levels over 14 days of treatment [50]. When comparing the 3 mg GB0139 group with placebo on 
day 14, five high relevance plasma markers (PDGF -BB, PDGF -AA, PAI -1, YKL -40 and MCP 
1) associ ated with IPF pathogenesis were either significantly reduced or showed a trend for 
reduction [50]. In addition, there was a correlation between the change in lung Gal -3 levels and 
the change in plasma levels of the high rel evance biomarkers across the 3 mg and 10 mg groups 
(see IB for details ). Therefore, these reductions in plasma biomarkers were associated with the 
GB0139 -induced reduction in Gal -3 expression on AMs and support the lung PK/PD as the key 
driver of the obser ved systemic biomarker changes. These observations, coupled with AM Gal -3 
target engagement data on 3 mg GB0139 , indicated potential efficacy at this dose level in IPF 
which supports the further evaluation of 3 mg in the present study. 
The 3 mg GB0139 dose was also well tolerated in healthy participants and participants with IPF 
in the phase I study.
Dosing
Following Protocol version 6.1_UK, subjects eligible for the study will be randomised into 2:1 
ratio to one of twotreatment arms:
A.GB0139 3mg once a day (2x 1.5mg capsules) by inhalation 
B.Placebo once a day (2x placebo capsules) by inhalation
7.0 STUDY POPULATION
Prospective approval of protocol deviations to enrolment criteria, also known as protocol 
waivers, is not permitted.
Inclusion Criter ia
Each subject must meet all of the following inclusion criteria in order to be enrolled in the study/
randomized to treatment:6.5
6.6
7.1
Galecto Biotech AB Page 28 of 105
GALACTIC -1 v7.1_UK 28 January 2022
1.Male and female subjects aged ≥ 40 years of age with a diagnosis of IPF established 
during the previous five years according to ATS/ERS/Fleischner criteria [ 1-3].A 
diagnostic HRCT scan assessed according to the ATS/ERS/Fleischner criteria should be 
available from within the 12 months (up to 12 months + 27 days) prior to screening. 
Note: a separate HRCT scan will notbe performed as part of the study. Diagnostic 
HRCTs will be subject to central reading for assessing study eligibility.
2.Lung function parameters as follows:
a.FVC > 45% of the predicted value at screen ing
b.DLCO (corrected for Hb) of 30% to 79% of the predicted value at screening.
3.Participants who currently are not being treated with nintedanib or pirfenidone; or cannot
tolerate nintedanib or pirfenidone .
4.Subjects must sign and date a written, IRB/EC appr oved informed consent form and any 
required authorization prior to initiation of any study procedures.
Exclusion Criteria
Subjects meeting any of the following exclusion criteria are not to be enrolled in the 
study/randomized to treatment :
1.Currently has si gnificant airways obstruction: FEV1/FVC ratio of < 0.7 at screening .
2.Has clinical evidence of active infection, including, but not limited to, bronchitis, pneumonia, 
sinusitis, urinary tract infection, and cellulitis.
3.Has a history of malignancy within the last 2 years with the exception of basal cell 
carcinoma, squamous cell carcinoma of the skin (localised, treated or cured), chronic 
lymphocytic leukaemia (under observation) and prostate cancer requiring anti -androgens, 
localised treatment (minor surgery, radiotherapy) and/or managed by observation.
4.Has any condition other than IPF that, in the opinion of the investigator, is likely to result in 
the death of the subject within the next 2 years.7.2
Galecto Biotech AB Page 29of 105
GALACTIC -1 v7.1_UK 28 January 2022
5.Presence of other disease that may interfere with testing proc edures or in the judgement of 
the Investigator may interfere with trial participation or may put the patient at risk when 
participating in this trial .
6.Is likely to receive lung transplantation within the next 12 months.
7.Currently receiving nintedanib, pirfenidone, high dose corticosteroid, cytotoxic (e.g., 
chlorambucil, azathioprine, cyclophosphamide, methotrexate), vasodilator therapy for 
pulmonary hypertension (e.g., bosentan), also see prohibited medications (Section 8.3.2). A 
current dose of less than or equal to 15 mg/day of prednisone or its equivalent is acceptable if 
the dose is anticipated to remain stable during t he study. 
8.Prior use of GB0139 or previously randomi zed in GALACTIC -1. 
9.
Prior use of nintedanib or pirfenidone within 7 days of initiation of screening.
10.Prior use of investigational drugs within 30 days (or 5 half -lives, whichever is longer) of 
initiation of screening.
11.Participating in another interventional clinical trial. 
12. Has a history of unstable or deteriorating cardiac or pulmonary disease (other than IPF) 
within the previous six months, including, but not limited to, the following:
a.Unstable angina pe ctoris or myocardial infarction, or percutaneous coronary 
intervention within the last 6 months .
b.Congestive heart failure requiring hospitalization .
c.Uncontrolled clinically significant arrhythmias. 
13.If female, the subject is pregnant or lactating or intending to become pregnant before 
participating in this study during the study and within 33 days after last dose of the study 
drug; or intending to donate ova during such time period. 
14.Woman considered to be of childbearing potential who do not use highly effective birth 
control methods (A/B/C) during the study and for 33 days after last administration of study 
drug. Female subjects will be considered to be of childbearing potential unless surgically 
Galecto Biotech AB Page 30of 105
GALACTIC -1 v7.1_UK 28 January 2022
sterilised by hysterectomy or bilateral tubal ligation, or postmenopausal for at least 12 
months .
A.Highly effective methods of birth control (when used consistently and correctly) are: 
ointrauterine device (IUD) placed at least 4 weeks prior to the IMP adminis tration
obilateral tubal occlusion
.
ovasectomised partnerB.
osexual abstinenceC.  
ocombined (estrogen and progestogen containing) hormonal contraception associated with inhibition of 
ovulation: oral, intravaginal, transdermal. 
oprogestogen -only hormonal contr aception associated with inhibition of ovulation: oral, injectable, 
implantable.
ointrauterine hormone -releasing system (IUS). 
B.Vasectomised partner is a highly effective birth control method provided that partner is 
the sole sexual partner of the woman of childbearing potential trial subject and that the 
vasectomised partner has received medical assessment of the surgical success.
C.Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study 
treatments. The reliability of sexual abstinence needs to be evaluated in rel ation to the 
duration of the clinical trial. 
15.Male partners of women of child bearing potential not committing to using condoms 
during the course of the study and 90 days after last administration of study drug, unless 
they have undergone male sterilizatio n (with appropriate post- vasectomy documentation 
of the absence of sperm in the ejaculate).
16.Hypersensitivity to the active substance ( GB0139 ) or the excipient (lactose).
Galecto Biotech AB Page 31 of 105
GALACTIC -1 v7.1_UK 28 January 2022
8.0 STUDY DRUG
Study Drug Administration 
Both GB0139 (3mg) as well as the placebo will be administered viainhalation once a day us ing
the Plastiape RS01 Monodose DPI device (a CE marked device).
All subjects must be trained in the use of the inhaler device at w0/baseline, according to the 
instructions provided with the device ( Appendix 1 in Section 18.0). Placebo capsules and inhaler 
devices will be provided for training and demonstration purposes. Site staff should be assured the 
subject will be able to administer the drug at home safely and competently. The same DPI 
devices can be used for training throughout the study but must not be used for dosing. Study site 
personnel will dispense the IMPs, a nd site personnel will facilitate administration when the 
subject is in the clinic, at the time of w0/baseline, however subjects themselves will hold the DPI 
device during inhalation. At subsequent visits up until study completion/withdrawal the subject’s 
technique with the DPI device should be assessed to ensure correct usage and further instruction 
given if required/requested.
Capsules will be loaded into the DPI device as per the instructions provided with the device (and 
included in Appendix 1 ). A single device will be used per two weeks of dosing. The device will 
be dispensed with the IMP. One (1) to three (3) inhalations from the DPI device will be 
performed with each capsule. Any problems with drug administrat ion will be noted in the CRF.
Site staff will instruct the subject on how to take the drug, including the number of capsules to be 
inhaled each day and the timing of dose administration. On administration of the first dose the 
subject should be monitored a t the site for 1 hour to observe any acute adverse reaction to study 
medication (e.g., bronchospasm). The PI/attending physician may perform additional spirometry 
as part of their assessment if, in their opinion, it is safe to do so and would be helpful in the 
assessment of any such events. For daily doses taken at home, subjects should be advised to 
administer the study drug at approximately the same time of day. Subjects will be given DPI 
devices and enough supplies until their next visit (plus one week). Subjects will be encouraged to 
contact the site for additional advice and support if they have an issue whilst using the inhaler. 8.1
Galecto Biotech AB Page 32 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Subjects will also be instructed to bring back unused medication .Allused and unused blister
should be returned to site for accountability purposes. Individual used capsules can be discarded 
by the participant at home . 
Permitted medications
Vaccines that are available to study participants including but not limited to COVID -19, 
influenza and pneumonia vaccines.
Prohibited Medi cations including approved and non -approved medications for IPF
8.3.1 Medications approved for IPF
Nintedanib 
Pirfenidone
Following the most recent DSMB recommendation, the above approved medications for IPF are 
prohibited in GALACTIC -1, and if taken, should result in immediate exclusion from screening 
for the study, or withdrawal from the study treatment.
Under caring physician’s medical judgement, if deemed appropriate, patients with IPF may 
discontinue nintedanib or pirfenidone and be considered for screening after a wash out period of 
minimum 7 days . 
Following randomization, study participants are only permitted to take nintedanib or pirfenidone 
after withdrawals of the inhale d study treatment. 
8.3.2 Non- approved medications for IPF
Current guidelines recommend against use of a number of drugs, either alone or in combination, 
to modify disease progression in idiopathic pulmonary fibrosis, and the use of the following 
should be resul t in exclusion from the study: 
• N- acetylcysteine
•Azathioprine
•Ambrisentan8.2
8.3
Galecto Biotech AB Page 33 of 105
GALACTIC -1 v7.1_UK 28 January 2022
•Bosentan
•Macitentan
•Mycophenolate mofetil
•Warfarin (disallowed only when prescribed solely for the treatment of IPF and is 
permitted for other recognised indications such as Atrial Fibrillation)
Management of Clinical Events 
Management of all types of adverse events, regardless of the possible underlying cause is the 
responsibility of the treating physician/investigator . 
Blinding and Unblinding procedures
8.5.1 Blinding
This study is a double -blind study which will be maintained throughout the study, including the 
follow -up period. Study medication is identified by a medication code number. Packaging and 
labelling will be otherwise identical. Subjects, Investigators and everyone involved in analysing 
or with an interest in this double -blind study (Sites, Study team, CRO s, other service providers) 
will remain blinded with regard to the randomised treatment assignments until after database 
lock. Only the D SMB will have access to unblinded information. An IVRS/IWRS will be used to 
assign subjects to treatment groups at study start. The randomisa tion code will be kept 
undisclosed up to database lock. 
8.5.2 Unblinding
If the Investigator believes that knowledge of the IMP received by a subject is essential for 
appropriate treatment of an AE, the Investigator should ideally consult with the CRO/Galecto 
before breaking the code. In any event, the Investigator should inform Galecto Biotech AB 
(subsequently referred to as Galecto) as soon as possible whenever the code has been broken for 
a subject. In the event that the site requires emergency access to an i ndividual subject code and 
personnel from Galecto are not available, each site may break the blind without any prior 
consultation. In such an event, the Chief Investigator, Principal Investigator or delegate would 8.4
8.5
Galecto Biotech AB Page 34 of 105
GALACTIC -1 v7.1_UK 28 January 2022
notify Galecto as soon as possible via email or fax. If the Investigator needs to break the blind 
for an individual subject, the date and reason will be recorded in the subject’s CRF. The 
IVRS/IWRS will provide a telephone/web procedure for unblinding the code to the Investigator / 
Pharmacist / in vestigational drug storage Manager. The Investigator will not reveal the unblinded 
treatment code to any other member of the clinical team involved in the study or to the Study 
Monitor. If the code is broken for any individual subject, the subject will be withdrawn from the 
study and the procedures accompanying the withdrawal visit performed. If the code is broken 
without justification, this will be deemed a serious protocol violation.
To avoid unblinding of the study team through drug safety reports which are to be unblinded as 
per regulatory requirements, a procedure will be maintained to keep code -breaking in these cases 
unknown to the study team.
Description of Investigational Agents 
The planned dose levels (3and 10 mg GB0139 ) have been selected in the original study design 
(Protocol version 5. 1_UK) following review of non -clinical pharmacokinetic, safety 
pharmacology and toxicology data. Pharmacokinetic, toxicokinetic and toxicology studies in 
mice, rats and dogs indicate the drug is readily bioavaila ble via the inhaled route with little or no 
accumulation after 14 -daydosing and is excreted in the faeces with a t1/2 of approximately 6 h.
Given the lack of adverse effects seen in the two species as well as the favourable safety profile 
seen in the phas e I/IIa in healthy volunteers and IPF subjects, no direct anticipated adverse drug 
specific side effects are expected in the current study, nor are any drug interactions anticipated 
given the clear cytochrome profiling. Further details regarding non -clinic al pharmacokinetic, 
safety pharmacology and toxicology data can be found in the IB.
Packaging and Labeling 
The IMPs will be prepared by the sponsor and supplied to the Investigator. The Sponsor must 
ensure that the Investigator is notified prior to dispat ch of IMP supplies, and of the anticipated 
date of their arrival. The IMP is shipped upon firstscreening, then arrives on site prior to dosing.8.6
8.7
Galecto Biotech AB Page 35 of 105
GALACTIC -1 v7.1_UK 28 January 2022
The IMPs must be received at each Investigational site by a designated person, handled and 
stored safely and pr operly, and kept in a secured location to which only the Investigator and 
designated staff have access. After a review of the temperature monitors included with shipments 
the Sponsor /CRO must ensure that it is confirmed that the transportation conditions w ere 
acceptable.
Storage, Handling, and Accountability 
Following the Sponsor’s approval, all remaining IMP will either be returned to the Sponsor or 
sent for destruction within 8 weeks of completion of the study -dosing period.
All used IMP containers and u nused IMP will be held under quarantine in the investigator site 
facility pending accountability/return/destruction .8.8
Galecto Biotech AB Page 36 of 105
GALACTIC -1 v7.1_UK 28 January 2022
9.0 STUDY END POINTS
Primary Endpoint
• T he annual rate of decline in Forced Vital Capacity (FVC; expressed in mL over 52 
weeks) .
Key Secondary Endpoints
•Proportion of subjects with an absolute decline from baseline in FVC (% pred) of ≤10% 
at Week 52.
•Change from baseline in SGRQ total score at Week 52.
•Time to first hospitalization ( respiratory related, including acute exacerbation of I PF).
•Time to death (all -causes). 
Secondary endpoints 
•Proportion of subjects with an absolute decline from baseline in FVC % pred of ≤5% at 
w52.
•Change from baseline in 6 -minute walk test (6MWT) distance over 52 weeks .
•Change from baseline in diffusion c apacity of the lung for carbon monoxide (DLCO), 
corrected for HB, over 52 weeks .
•Change from baseline at week 52 for dyspnoea assessment by University of California 
San Diego -Shortness of Breath Questionnaire (UCSD -SOBQ) .
•Change from baseline at week 52 for HRQoL as assessed by Short Form Survey (SF -36).
•Percentage of subjects with Adverse Events (AE) or Serious Adverse Events (SAE) .
•Time to first hospitalization (IPF related, including acute exacerbation of IPF) .
•Time to first hospitalization ( all cause) .
•Time to respiratory- related death.
•Time to initiation of nintedanib or pirfenidone .
•Change in FVC expressed in mL over 52 weeks for subjects who have never been treated 
with pirfenidone or nintedanib.9.1
9.2
9.3
Galecto Biotech AB Page 37 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Safety Endpoints
•The following measure of safety will be assessing throughout the study:
•Vital signs 
•Physical examination 
•Weight 
•Clinica l laboratory tests (haematology, clinical chemistry and urinalysis) 
•Adverse events (see Section 11.0)
•12-lead electrocardiogram (ECG)
Exploratory Endpoints
9.5.1 Biomarkers
Change from baseline in selected biomarkers including but not limited to: YKL 40, PAI 
1, PDGF -BB, MCP -1, CCL -18, KL -6, CA -125, CA -19, Gal- 3 and collagen neoepitopes –
described in Appendix 2 (Section 18.0) –over time up to week 52 in all subjects.
9.5.2 Initiation or termination of nintedanib and pirfenidone in the previous stratified 
study population 
9.5.3 Time to initiation of pirfenidone or nintedanib treatment for SoC2 participants up 
to the time when SoC1 and SoC2 were removed in the study .Pharmacogenetics
The study includes a pharmacogenetic component including but not limited to analysis of 
GAL -3 and IPF disease related genes of interest that might relate to the efficacy and/or 
safety of GB0139 . 9.4
9.5
Galecto Biotech AB Page 38 of 105
GALACTIC -1 v7.1_UK 28 January 2022
10.0 STUDY CONDUCT
This trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), 
applicable regulatory requirements, and International Conference on Harmonisation (ICH) 
guidelines.
Study Personnel and Organizations
The contact information for th e project clinician for this study, the clinical laboratories, the 
coordinating investigator for each member state/country, the interactive voice response system 
(IVRS)/interactive web response system (IWRS) provider, the contract research organization 
(CRO) team may be found in the Investigator Site File . A full list of investigators is available in 
the sponsor’s investigator database.
Arrangements for Recruitment of Subjects
Recruitment and enrollment strategies for this study may include recruitment from the 
investigator’s local practice/hospital or referrals from other physicians. If advertisements become 
part of the recruitment strategy, they will be reviewed by the institutional review board 
(IRB)/independent ethics committee (IEC). 
Enrollment strategies for this study may include the following:
Review of local practice/hospital database
Communication with other physicians/colleagues and cooperating health care facilities 
that regularly refer subjects for further diagnosis and care
Visit schedule 
Ther e is a screening visit and 7study visits planned over the 52 weeks treatment period. A safety 
follow up will be conducted via phone 7 days after the final visit.
10.3.1 Screening & Randomisation
After giving his/her Informed Consent, the patient may be selected based on inclusion and 
exclusion criteria for the study at visit 1. The shipment or transfer of HRCT for review can be 10.1
10.2
10.3
Galecto Biotech AB Page 39of 105
GALACTIC -1 v7.1_UK 28 January 2022
organised before the screening visit provided the pa rticipant has given and signed his Informed 
Consent. The screening is up to 6 weeks. 
The participants will be randomised at visit 2 if all inclusion and exclusion criteria are fulfilled.  
The results of laboratory parameters from visit 2 may only become available 24 to 72 hours after 
visit 2. Therefore, laboratory results from visit 2 can not qualify as exclusion criteria. However, in 
case these results would retrospectively fulfil an exclusion criterion, the patient will be 
withdrawn unless continuation is justified in writing by the Investigator. 
10.3.2 Re-screening visit
If a subject fails to meet the screening criteria for reasons which the Principal Investigator judges 
to be anomalous or the result of a temporary factor, those test(s) may be repeated once at an ad 
hoc visit(s), providing the subjects is still within the six weeks screening window. Subjects who 
fail screening and are outside the six weeks screening window, whom the Principal Investigator 
judges to now meet the screening criteria will be permitted to undergo rescreening one additional 
time, with advanced ap proval from Syneos Health Medical Monitors .
If a re -
screening visit occurs within 12 weeks of initial screening it is not required to repeat PFT 
and DLCO , if the PFT and DLCO measured at the initial screening have met study inclusion 
criteria .  
10.3.3 Treatment period
There will be seven study visits during the treatment period as follows: at randomization/baseline 
(w0), w4, w8, w12, w26, w40, and w52. Details for the data collected at each visit are given in 
the time and events table (Section 2.2). Visits 3, 4 and 5 should occur within ± 3 days of the 
scheduled time point. Visits 6 and7 should occur within 7 days of the scheduled time point. 
10.3.3.1 Participants randomized prior to Protocol version 6. 1_UK and eligible to continue 
participation 
Participants who were already randomised and eligible to remain in GALACTIC -1 and continue 
to receive blinded study treatment (3 mg GB0139 or placebo) should attend visits as required by 
Galecto Biotech AB Page 40 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Protocol ver sion 5. 1_UK until Protocol version 6.1_UK is approved. Once the amended ICF is 
approved they should be re -consented. Participants who have completed w52 visit by the time 
the Protocol version 6. 1_UK is approved should attend a withdrawal visit as soon as possible 
followed by a phone call follow up as specified in the Protocol version 6. 1_UK . 
10.3.4 Study treatment completion and Follow -up period
Subjects will be considered to have completed the study treat ment period if assessments 
according to the protocol at week 52 have been performed. At the end of the treatment period 
subjects will enter a follow -up period. Follow -up phone call can be performed from 7 days and 
up to 14 days after the last study visit o r withdrawal visit.
Additional individual visits may be scheduled by the treating physician on a case by case basis.
Data collected at these visits will be recorded as unscheduled visits in the eCRF .
At all scheduled visits, study site staff will collect t reatment patterns and outcomes, vital status, 
clinical events, AE/SAE data from the charts of study subjects followed at the participating sites. 
Study procedures
10.4.1 Data collection
An electronic case report form (eCRF) system will be utilized for data colle ction, monitoring, 
and quality control. Data validation will be programmed in the eCRF system to automate data 
queries. The physician or assigned study personnel will complete the eCRFs at every visit, and as 
required by the protocol.
If clarifications are needed, queries will be raised either by the monitor of the study or the 
assigned data management team, through the built -in query management functionality in the 
eCRF. The physician or assigned study personnel will be required to respon d to these queries 
through the eCRF system.
Subject data collected on eCRFs during the study will be recorded in an anonymous fashion to 
ensure subject confidentiality. The physician must maintain source documents where relevant for 10.4
Galecto Biotech AB Page 41of 105
GALACTIC -1 v7.1_UK 28 January 2022
each subject in the stu dy, consisting of all demographic and medical information, and keep the 
written informed consent form. All information on the eCRFs must be traceable to these source 
documents in the subject’s medical file. 
Initiation of the participating sites will be performed by the designated CRO s. Before study 
initiation, a CRO representative will review the protocol, the CRF and the eCRF system with the 
physicians and their staff. CROs will follow streamlined SOPs that have 
been reviewed and 
approved by Galecto.
Conc omitant or prior medications entered into the database will be coded using the World Health 
Organization (WHO) Drug Reference List. Medical history/current medical conditions and 
adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
terminology.
10.4.2 Informed Consent
Each subject must provide written informed consent before any study -required procedures are 
conducted, and before the diagnostic HRCT can be sent for central review.
10.4.3 Subject Demographics
Subject demographics wi ll be collected at screening visit 1.
• Age at baseline
•Gender
•Height and body weight (for BMI computation)
10.4.4 Medical History
During the Screening period, a complete medical history will be compiled for each subject. The 
following variables will be collected:
•Smoking history, recorded in pack- years
•Pre-existing conditions
Galecto Biotech AB Page 42of 105
GALACTIC -1 v7.1_UK 28 January 2022
•Time of IPF diagnosis by HRCT or surgical lung biopsy
•
Time of start of treatment with pirfenidone or nintedanib (as appropriate)
•Time point and reason for discontinuation of treatme nt with pirfenidone or nintedanib (as 
appropriate)
•Any episode of acute exacerbation in the subject’s IPF context during three months prior 
to randomization
•Any  medication used prior to screening including vaccinations
10.4.5 Physical Examination
A physical examination will be completed as per standard of care at all visits.
10.4.6 Vital Signs
Vital sign measurements include supine (after at least 5 minutes in this position) measurements 
of diastolic and systolic blood pressure, heart rate, and body temperature. They wi ll be conducted 
at all visits.
10.4.7 Health -related Quality of Life Questionnaires
Three patient-reported assessments related to symptoms and quality of life will be collected 
during the study. A version of each will be to the site and will be completed by each subject at 
the visits as per the T&E table Section 2.2
St George’s Respiratory Questionnaire (SGRQ) a validated QoL for IPF 
The Short Form Health -36 survey 
The University of California San Diego, shortness of breath questionnaire (UCSD -
SOBQ) 
Galecto Biotech AB Page 43of 105
GALACTIC -1 v7.1_UK 28 January 2022
10.4.8 12-Lead Electrocardiogram
Safety monitoring by ECG will be performed using site local equipment. PR interval, QRS 
duration, QT interval and QTcF are required to be evaluated
.
10.4.9 Clinical Laboratory Evaluations
Clinical laboratory evaluations will be performed b y a central laboratory as outlined below.
Blood samples for analysis of the clinical chemistry and hematological parameters, urinalysis 
and biomarkers are shown in Table 2, Table 3and Table 4.
Table 2: Clinical Chemistry and Hematology Tests
Hematology Serum Chemistry
Hematocrit
Hemoglobin
Leukocytes with differential count
Platelet (count)Albumin
Alkaline phosphatase (ALP)
Aspartate transaminase ( AST)
Alanine transaminase ( ALT )
Bilirubin (total)
Calcium
CreatinineGlucose
Potassium
Sodium
Table 3: Clinical Urinalysis Tests
                            Urinalysis
Bilirubin
Glucose
Ketones
Leukocytes
Nitrite
Occult bloodpH
Protein
Specific gravity
Turbidity and color
Urobilinogen
Results are recorded qualitatively as:  -, +, ++, +++
Galecto Biotech AB Page 44of 105
GALACTIC -1 v7.1_UK 28 January 2022
10.4.10 Pregnancy Test
A serum pregnancy (choriogonadotropin beta) test will be completed by all females of 
child
-bearing potential during screening; this test must be negative for the subject to be enrolled. 
Urinary pregnancy tests will then be repeated at various times during the study as specified in the 
Time & Events table. 
Any occurrence of a pregnancy in a subject undergoing treatment in the GALACTIC- 1 study 
must be reported according to the rules agreed upon with the designated CRO within 24 hours of 
learning of its occurrence. The pregnancy should be followed -up via fax or email to determine
outcome, including spontaneous or voluntary termination, details of the birth, and the presence or 
absence of any birth defects, congenital abnormalities, or maternal and/or new -born 
complications.
Pregnancy should be recorded on a Pharmacovigilance Pregn ancy Form and reported by the
treating physician or other involved health care professional to Galecto’s Pharmacovigilance 
(PV) representative. In case of any congenital abnormality, birth defect or maternal and new -
born complications, the possible relatio nship to the Galecto drug should be reported.
Additionally, any SAE experienced during pregnancy must be reported into the eCRF system.
Note: should the eCRF system become non -operational, the site must complete the appropriate
paper Serious Adverse Event Form . The completed form is then faxed/mailed within 24 hours of 
the Investigator’s or site’s awareness; however, the reported information must be entered into the 
eCRF system once it becomes operational. Please see Section 11.2 for PV reporting information .
10.4.11 Biomarkers 
A serum sample for the assessment of biomarkers will be collected at baseline (visit 2) and 
weeks 4, 12, 26 and 52. The list in Table 4gives examples of biomarkers potentially related to 
Galectin- 3 activity and/or IPF disease severity/prognosis. More detail on the rationale for 
including such biomarkers is described in Appendix 2 (Section 18.0). Ultimately, individual 
biomarkers may be added to or removed from this list.
Galecto Biotech AB Page 45of 105
GALACTIC -1 v7.1_UK 28 January 2022
Table 4: Biomarker Panel
                                                                  Serum Biomarkers 
Gal-3
Collagen neoepitopes
YKL -40    
MCP -1
CA-125                                           KL-6
PAI-1
PDGF-BB
CCL -18
CA-19
10.4.12 Genetics Sample
All subjects will be asked for a blood sample for genetic assessment. However, this is not 
mandatory for the subject to participate in the study. A single sample will be taken at visit 2 or at 
any visit throughout the study and processed or stored after separate informed conse nt is given in 
accordance with local ethical and regulatory requirements. The sample will be anonymised, 
meaning there will be no way to trace back to the identity of the donor. Samples will be stored 
for up to 15 years after the end of the study or until there is no more material available for tests.
10.4.13 Spirometry
Equipment and manual will be provided by Clario (previously ERT) . Data will be centrally 
evaluated by Clario . 
10.4.14 Pulse Oximetry  
Pulse oximetry will be measured using sites local equipment . 
10.4.15 DLCO
Sites use local equipment to measure DLCO using a manual provided by Clario . Data will be 
centrally overread by Clario . 
10.4.16 6MWT
Test manual will be provided by Clario . 
10.4.17 HRCT central overread
HRCT will be reviewed by an independent Chest radiologist, assigned by Clario , who will assess 
according to the ATS/ERS/Fleischner criteria [ 1-3].
Galecto Biotech AB Page 46 of 105
GALACTIC -1 v7.1_UK 28 January 2022
10.4.18 Concomitant Medications and Procedures
Medications including vaccination used by th e subject will be recorded in the electronic case 
report form (eCRF) to cover screening period and then prospectively at all study visits (treatment 
and follow up periods) until study completion/withdrawal. See Section 8.3.2 for a list of 
medications and therapies that are prohibited during the study.
10.4.19 Adverse Events
Monitoring of AEs, serious and nonserious, will be conducted throughout the study as specified 
in the Time and Events Table (Section 2.2). Refer to Section 11.0 for details regarding 
definitions, documentation, and reporting of pretreatment events (PTEs), AEs, and SAEs. 
Discontinuation of study t reatment 
Temporary discontinuation of GB0139 for <2 weeks will be permitted, if for reasons other than 
those stated below. The reason for discontinuation should be documented in the eCRF.
Treatment with study drug may be permanently discontinued for any of the following reasons:
•Persistent non- adherence by subject
•Adverse event assigned to the investigational drug
•Overall unsatisf actory therapeutic response
•Study terminated by sponsor
•Withdrawal by subject
•Lost to follow -up
•Other (cause to be elaborated on in the subject’s file)
In all cases, participants should be encouraged to discuss any potential study treatment 
discontinuation with the investigator prior to stopping treatment. If considered medically 
appropriate by the PI, participants who have been withdrawn from study treatment can remain in 
the study, resume their usual standard of care treatment for IPF, if applicable, and complete 
scheduled visits and study assessments up to the follow up phone call.
Withdrawal of Subjects from the Study
Subjects may withdraw for the following reasons :10.5
10.6
Galecto Biotech AB Page 47 of 105
GALACTIC -1 v7.1_UK 28 January 2022
•Lost to follow -up
•Study terminated by sponsor
•Withdrawal by subject
•Completed study
•Death
•Lung transplant
•Other (cause to be elaborated on in the subject’s file)
All study procedures outlined for the withdrawal visit will be completed as specified in the Time 
and Events Table ( Section 2.2). The primary reason for study drug discontinuation will be 
recorded on the eCRF. 
Following the study withdrawal, no new information will be collected from the withdrawn 
subject and added to the existing data or any da tabase.
Study Compliance
Study drug will be administered or dispensed only to eligible subjects under the supervision of 
the investigator or identified sub- investigator(s). The appropriate study personnel will maintain 
records of study drug receipt and dis pensing.10.7
Galecto Biotech AB Page 48 of 105
GALACTIC -1 v7.1_UK 28 January 2022
11.0 ADVERSE EVENTS
Definitions
11.1.1 Pretreatment Event Definition
A pretreatment event (PTE) is any untoward medical occurrence in a subject who has signed 
informed consent to participate in a study but before administration of the first dose of study 
medication; it does not necessarily have to have a causal relationship with study participation.
11.1.2 Treatment Emergent Adverse Event
A treatment emergent adverse event (TEAE) is any untoward medical occurrence that emerges 
during treatment, having been absent pre -treatment or worsens relative to the pre -treatment state.
11.1.3 Adverse Event Definition
Adverse Event (AE) means any untoward medical occurrence in a subject or subject 
administered a pharmaceutical product; the untoward medical occurrence does not n ecessarily 
have a causal relationship with this treatment. An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) produc t whether or not it is related to the 
medicinal product. This includes any newly occurring event, or a previous condition that has 
increased in severity or frequency since the administration of study drug.
An abnormal laboratory value will not be assessed as an AE unless that value leads to 
discontinuation or delay in treatment, dose modification, therapeutic intervention, or is 
considered by the investigator to be a clinically significant change from baseline.
11.1.4 Serious Adverse Event Definition
Serious Adver se Event (SAE) means any untoward medical occurrence that at any dose:
Results in death.
Galecto Biotech AB Page 49of 105
GALACTIC -1 v7.1_UK 28 January 2022
Is life-threatening (refers to an AE in which the subject was at risk of death at the time 
of the event. It does not refer to an event which hypothetically might have caused death if 
it were more severe).
Requires subject hospitalization or prolongation of an existing hospitalization (see 
clarification in the paragraph in Section 11.2 on planned hospitalizations).
Results in persistent or significant disability or incapacity . (Disability is defined as a 
substantial disruption of a person’s ability to conduct normal life functions).
Is a congenital anomaly/birth defect ?
Is a medically important event . This refers to an AE that may not result in death, be 
immediately life threatening, or require hospitalization, but may be consi dered serious 
when, based on appropriate medical judgment, may jeopardize the subject, require 
medical or surgical intervention to prevent 
oneof the outcomes listed above, or involves 
suspected transmission via a medicinal product of an infectious agent. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in subject 
hospitalization, or the development of drug dependency or drug abuse; any organism, 
virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform 
encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.
Clarification should be made between an SAE and an AE that is considere d severe in intensity 
(Grade 3 or 4), because the terms serious and severe are NOT synonymous. The general term 
severe is often used to describe the intensity (severity) of a specific event; the event itself, 
however, may be of relatively minor medical significance (such as a Grade 3 headache). This is 
NOT the same as serious , which is based on subject/event outcome or action criteria described 
above and is usually associated with events that pose a threat to a subject’s life or ability to 
function. A sever e AE (Grade 3 or 4) does not necessarily need to be considered serious. For 
example, a white blood cell count of 1000/mm3to less than 2000 is considered Grade 3 (severe) 
Galecto Biotech AB Page 50 of 105
GALACTIC -1 v7.1_UK 28 January 2022
but may not be considered serious. Seriousness (not intensity) serves as a guide for defining 
regulatory reporting obligations.
Procedures for Recording and Reporting Adverse Events and Serious 
Adverse Events
All AEs spontaneously reported by the subject and/or in response to an open question from study 
personnel or revealed by observation , physical examination, or other diagnostic procedures will 
be recorded on the appropriate page of the eCRF (see Section 11.3 for the period of obs ervation).  
Any clinically relevant deterioration in laboratory assessments or other clinical finding is 
considered an AE. When possible, signs and symptoms indicating a common underlying 
pathology should be noted as 1 comprehensive event.
Regardless of ca usality, SAEs and serious pretreatment events (as defined in Section 11.1) must 
be reported (see Section 11.3 for the period of observation) by the investigator to Galecto’s 
pharmacovigilance representative or designee (contact information provided belo w). This should 
be done by faxing/mailing the paper SAE Form within 24 hours after becoming aware of the 
event before recording the SAE into the eCRF system . Follow -up information on the SAE or 
serious pretreatment event may be requested by Galecto. SAE re port information must be 
consistent with the data provided on the eCRF. The SAE Form, created specifically by Galecto 
(or by the designated CRO), will be provided to each clinical study site.11.2
Galecto Biotech AB Page 51of 105
GALACTIC -1 v7.1_UK 28 January 2022
11.2.1 SAE Reporting Contact Information:
E
-mail: PhV_ZZA31672_SO@IQVIA.com
Fax number: 
Country Toll-Free Fax No. 
INDIA 000-800001-6750 
Planned hospital admissions or surgical procedures for an illness or disease that existed before 
the subject was enrolled in the trial orbefore study drug was given are not to be considered AEs 
unless the condition deteriorated in an unexpected manner during the trial (e .g.surgery was 
performed earlier or later than planned).
For both serious and nonserious AEs, the investigator must determine both the severity (toxicity 
grade) of the event and the relationship of the event to study drug administration. For serious 
pretreatment eve nts, the investigator must determine both the severity (toxicity grade) of the 
event and the causality of the event in relation to study procedures.
Relationship of the event to study drug administration (i
.e., its causality) will be determined by 
the inve stigator responding yes (related) or no (unrelated) to this question: “Is there a reasonable 
possibility that the AE is associated with the study drug?”
Galecto Biotech AB Page 52 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Monitoring of Adverse Events and Period of Observation
AEs, both nonserious and serious, will be moni tored throughout the study as follows: 
•AEs will be reported from the signing of informed consent through 30 days after 
administration of the last dose of study drug and recorded in the eCRFs.    
•SAEs .
•Serious pretreatment events will be reported to the Galecto pharmacovigilance 
representative or designee from the time of the signing of the informed consent form up 
to first dose of study drug and will also be recorded in the eCRF. 
•Related and unrelated treatment -emergent SAEs will be reported to the Galecto 
pharmacovigilance representative or designee from the first dose of study drug through 
30days after administration of the last dose of study drug and recorded in the eCRF. 
After this period, only rel ated SAEs must be reported to the Galecto pharmacovigilance 
representative or designee. SAEs should be monitored until they are resolved or are 
clearly determined to be due to a subject’s stable or chronic condition or intercurrent 
illness(es).
Procedures for Reporting Drug Exposure During Pregnancy and Birth Events
If a woman becomes pregnant or suspects that she is pregnant while participating in this study, 
she must inform the investigator immediately and permanently discontinue study drug. The 
sponsor m ust also be contacted immediately by faxing a completed Pregnancy Form to the 
Galecto pharmacovigilance representative or designee (see Section 11.2). The pregnancy must be 
followed for the final pregnancy outcome.
If a female partner of a male subject becomes pregnant during the male subject’s participation in 
this study, the sponsor mus t also be contacted immediately by emailing a completed Pregnancy 
Form to the Galecto pharmacovigilance representative or designee (see Section 11.2). Every 
effort should be made to follow the pregnancy for the final pregnancy outcome.11.3
11.4
Galecto Biotech AB Page 53 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Procedures for Reporting Product Complaints or Medication Errors (Including 
Overdose)
A product complaint is a verbal, written, or electronic expression that implies di ssatisfaction 
regarding the identity, strength, purity, quality, or stability of a drug product.  Individuals who 
identify a potential product complaint situation should immediately report this via the phone 
numbers or e -mail addresses provided below.
A me dication error is a preventable event that involves an identifiable subject and that leads to 
inappropriate medication use, which may result in subject harm. Whereas overdoses and 
underdoses constitute medication errors, doses missed inadvertently by a sub ject do not. 
Individuals who identify a potential medication error (including overdose) situation should 
immediately report this via the phone numbers or e -mail addresses provided in Section 11.2.1.
Product complaints in and of themselves are not AEs.  If a product complaint results in an SAE, 
an SAE form should be completed and sent to IQVIA (refer to Section 11.2).
Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
A designated CRO will be responsible for reporting all suspected unexpected serious adverse 
reactions (SUSARs) an d any other applicable SAEs to regulatory authorities, including the 
European Medicines Agency (EMA) ,investigators and IRBs or IECs, as applicable, in 
accordance with national regulations in the countries where the study is conducted. Relative to 
the firs t awareness of the event by/or further provision to the sponsor or sponsor’s designee, 
SUSARs will be submitted to the regulatory authorities as an expedited report within 7 days for 
fatal and life -threatening events and 15 days for other serious events, u
nless otherwise required 
by national regulations. The sponsor will also prepare an expedited report for other safety issues 
where these might materially alter the current benefit -risk assessment of an investigational 
medicinal product or that would be suff icient to consider changes in the investigational 
medicinal product’s administration or in the overall conduct of the trial. The investigational sites 
will also forward a copy of all expedited reports to their IRB or IEC in accordance with national 
regulat ions.11.5
11.6
Galecto Biotech AB Page 54 of 105
GALACTIC -1 v7.1_UK 28 January 2022
12.0 SAFETY MONITORING
Data and Safety Monitoring Board (DS MB)
An independent Data and Safety Monitoring Board (DSMB) will be implemented. Members of 
the D SMB selected and appointed by the sponsor will be fully independent of any ties to the 
trial, the sp onsor, or any other activity or entity that might affect their objectivity. The 
establishment and management of the D SMB isprescribed by a charter and provide sreports to 
the study team, sponsor, CRO. The minutes of all DSMB meetings will be stored in the Trial 
Master File (TMF).
The D SMB will continue to conduct regular review of the trial safety data, with the focus on the 
following safety information: 
• Death cases 
• Serious adverse events 
• Adverse events leading to withdrawal from study
The D SMB will recommend continuing , modifying or stopping the study based on these reviews. 
The D SMB iscommitted to meet and to make timely decisions. The D SMB will inform the 
coordinating Investigator of the trial, the Sponsor, and the Trial team if any urgent de cision has 
to be implemented. 
Event Adjudication
Following study read -out, Galecto may decide to employ an independent adjudication panel to 
review, in a blinded manner, events reported in the study including but not limited to all cases of 
death (the pri mary cause of death )and reported acute IPF exacerbations (based on written 
clinical reports, for diagnostic confirmation). See Appendix 3 (Section 18.0)for a definition of 
acute exacerbation in IPF. 12.1
12.2
Galecto Biotech AB Page 55 of 105
GALACTIC -1 v7.1_UK 28 January 2022
13.0 DATA HANDLING AND RECORD KEEPING 
The full details of procedures for data handling will be documented in the Data Management 
Plan. If selected for coding, AEs, PTEs, medical history, and concurrent conditions will be coded 
using the Medical Dictionary for Regulatory Activities (MedDRA). Drugs will be coded using 
the World Health Organization (WHO) Drug Dictionary.
eCRFs 
The designated CRO will supply investigative sit es with access to eCRFs and will make 
arrangements to train appropriate site staff in the use of the eCRF. The data collection forms are 
used to transmit the information collected to ensure quality and performance of this study to the 
sponsor, CRO partners , and regulatory authorities. Investigative sites must complete eCRFs in 
English.
After completion of the entry process, computer logic checks will be run to identify items, such 
as inconsistent data, missing data, and questionable values. Queries may be i ssued by the CRO 
personnel and will be answered by the site. Issues will be reconciled with Galecto.
Any change of, modification of, or addition to the data on the eCRFs should be made by the 
investigator or appropriate site personnel . Corrections to eCRFs are recorded in an audit trail that 
captures the old information, the new information, identification of the person making the 
correction, the date the correction was made, and the reason for change.
The principal investigator must review the eCRFs for c ompleteness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the principal investigator must retain 
full responsibility for the accuracy and authenticity of all data entered on the eCRFs .
eCRFs will be reviewed for comp leteness and acceptability at the study site during periodic 
visits by study monitors. The sponsor or its designee will be permitted to review the subject’s 
medical and hospital records pertinent to the study to ensure accuracy of the eCRFs. The 
completed eCRFs are the sole property of the sponsor and should not be made available in any 13.1
Galecto Biotech AB Page 56 of 105
GALACTIC -1 v7.1_UK 28 January 2022
form to third parties, except for authorized representatives of appropriate governmental health or 
regulatory authorities, without written permission of the sponsor.
Record Retention
The investigator agrees to keep the records stipulated in Section 13.1 and those documents that 
include (but are not limited to) the study -specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, all 
original signed and dated informed consent forms, subject authorization forms regarding the use 
of personal heal th information (if separate from the informed consent forms), electronic copy of 
eCRFs, including the audit trail, and detailed records of drug disposition to enable evaluations or 
audits from regulatory authorities, the sponsor or its designees. Any source documentation 
printed on degradable thermal sensitive paper should be photocopied by the site and filed with 
the original in the subject’s chart to ensure long term legibility. Furthermore, International 
Conference on Harmonisation (ICH) E6 Section 4.9.5 requires the investigator to retain essential 
documents specified in ICH E6 (Section 8) until at least 2 years after the last approval of a 
marketing application for a specified drug indication being investigated or, if an application is 
not approved, unt il at least 2 years after the investigation is discontinued and regulatory 
authorities are notified. No study document is to be destroyed without prior written agreement 
between Sponsor and the Investigator. Should the Investigator wish to assign the study records to 
another party or move them to another location, he/she must notify the Sponsor in writing of the 
new responsible person and/or the new location.13.2
Galecto Biotech AB Page 57 of 105
GALACTIC -1 v7.1_UK 28 January 2022
14.0 STATISTICAL METHODS
As part of Protocol version 6. 1_UK study design and objectives have been amended to focus on 
comparisons between GB0139 3mg and Placebo within the SoC2 strata (participants not 
currently treated with pirfenidone or nintedanib). All relevant subsections within this section 
have been amende d accordingly.
Statistical and Analytical Plans
A blinded data review will be conducted prior to database lock . This review will assess the 
accuracy and completeness of the study database, subject evaluability, and appropriateness of the 
planned statistica l methods.
A statistical analysis plan (SAP) will be prepared and finalized prior to database lock . This 
document will provide further details regarding the definition of analysis variables and analysis 
methodology to address all study objectives.
For desc riptive statistics categorical data will be presented as frequencies and percentages. 
Percentages will be based on the number of subjects with non -missing values for the 
corresponding categorical variable. Continuous data will be presented as number of subjects with 
non-missing values, mean standard deviation, median, minimum and maximum, as well as the 
25thand 75thpercentile.
All statistical tests as well as the confidence intervals will be two -sided. The study -wise type I 
error probability for the confi rmatory analys es is set to 10%. 90% confidence intervals are to be 
calculated, if feasible.
Covariates for the primary analyses will be pre -specified. For secondary analyses these are 
anticipated to be broadly similar to primary analysis but will be fully specified in the Statistical 
Analysis Plan (SAP).
Statistical Hypothesis
The primary efficacy analys es arebased on data from SoC2 only.14.1
14.2
Galecto Biotech AB Page 58 of 105
GALACTIC -1 v7.1_UK 28 January 2022
14.2.1 Primary efficacy endpoint s
The superiority of GB0139 3mg compared to Placebo (Plc) will be tested for the annual rate of 
decline in FVC in mL.
The null hypothes is is:
H0: There is no difference in the annual rate of decline in FVC in mL between GB0139
3mgand Plc .
The alternative hypotheses are:
Ha: There is a difference in the annual rate of decline in FVC in mL between GB0139
3mg and Plc.
14.2.2 Key Secondary Efficacy Endpoints:
The superiority of GB0139 3mg compared to Plc will be tested for the proportion of subjects 
with a decline ≤10% from baseline in predicted %FVC at week 52. The superiority of GB0139
3mg compared to Plc will be tested for the change from baseline in SGRQ total score at Week 
52.The superiority of GB0139 3mg compared to Plc will be tested for the time to first 
hospitalization (an y respiratory related, including acute exacerbation of IPF) during treatment.
The superiority of GB0139 3mg compared to Plc will be tested for time to death from all causes 
from date of randomization where time to death will be death at any time up to Wee k 52.
Analysis Sets
The following analysis sets will be used in this trial
Intention -to-Treat (ITT) Analysis Dataset -this includes all randomized subjects
Modified Intention- to-Treat Analysis Dataset (mITT) -this includes all randomized 
subjects with at least one application of study drug , and will be grouped according to the 
treatment they were randomised to.
Safety Analysis Dataset -this includes all randomized subjects with at least one 
application of study drug , and will be grouped according to the t reatment they received.14.3
Galecto Biotech AB Page 59 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Per-Protocol Analysis Dataset -this includes a subset of the subjects in the ITT analysis 
set who complied with the protocol sufficiently to ensure that these data would be likely 
to represent the effects of study intervention according to the underlying scientific model 
(e.g., subje cts who took at least 80% of study intervention treatment for at least 80% of 
the initial 52 weeks).
Primary Efficacy Analysis
The primary efficacy analysis will be based on data from SoC2 only. 
14.4.1 Analysis of Primary Efficacy Endpoint
The primary endpoint i s described in Section 9.1. The primary efficacy analysis is a random 
coefficient regression (random slopes and intercepts) model. Treatment andbaseline FVC (mL) 
will be included as a covariate in the analysis model. Other covariates such as age, and gender 
will be included as covariates unless their inclusion violates model assumptions or impacts 
stability. Baseline FVC is defined as the FVC result recorded at Visit w0/baseline, unless 
missing in which case the latest FVC before randomization in the subject’s chart result will be 
used.
The decrease in FVC is assumed to be linear within each subject over 52 weeks. The intercepts 
and slopes will be assumed to be normal ly distributed with arbitrary covariance matrix. The 
within -subject error will be assumed to be independent and normally distributed with mean zero 
and a common variance. The Kenward- Roger approximation will be used to estimate 
denominators degrees of free dom. 
Section 14.8 details of the approaches to handling of missing data are given .
Significance tests will be based on least -squares means; p- values and two -sided 90% confidence 
intervals for the difference between the treatment groups will be presented. An intent -to-treat 
principle will be used. Analyses will be implemented using SAS® Version 9.4 or higher. The 
assumptions for the primary analysis of decline in FVC will be tested; details will be provided in 
the SAP. The primary analysis will be based on observed data (but including retrieved drop out 14.4
Galecto Biotech AB Page 60of 105
GALACTIC -1 v7.1_UK 28 January 2022
measurements) and will assume remaining missing data are missing at random. The effect of 
missing data will be investi gated using multiple imputation methods which assume that subjects 
who discontinue treatment will no longer benefit from it in the future. See Section 14.8 for 
further details of these sensitivity analyses . 
Subgroup analyses will be fully specified in the SAP and will include: 
•Age
•Gender
•Race
•Ethnicity
•Previous treatment with pirfenidone and/or nintedanib
•Recruitment cohort (e .
g.,pre-or post -DSMB cutoff, and pre -or post -Protocol version 
6.
1_UK )
A cumulative distribution plot will be provided, showing the percentage of subjects by change 
from baseline in FVC in mL at week 52. 
Data will be summarized graphically and using summar y statistics.
14.4.2 Analysis of Secondary Endpoints 
For all secondary endpoints, an intent -to-treat principle will be used.
14.4.2.1 Key Secondary Endpoints
The key secondary analysis will be based on data from SoC2 only. Data will be summarized 
graphically and using su mmary statistics. The multiplicity procedure used for the key secondary 
endpoints will be detailed in the SAP.
Galecto Biotech AB Page 61of 105
GALACTIC -1 v7.1_UK 28 January 2022
Comparisons between treatment groups regarding the binary endpoint variable based on an 
absolute decline from baseline in FVC % pred
icted of ≤10% will be performed using a logistic 
regression model. Treatment and baseline FVC (mL) will be included in the model along with 
any other covariates included in the analysis of the primary endpoint . The likelihood- ratio test 
will be used to test for diff erences between treatments. Odds ratios together with 9 0% confidence 
intervals will be used to quantify the effect of treatment, comparing GB0139 3mgto placebo as 
the reference.
The change from baseline in the SGRQ total score at Week 52 will be analysed using a mixed 
model repeated measures with covariates treatment, baseline total score along with any other 
covariates included in the analysis of the primary endpoint.
The time to first hospitalization ( respiratory related, including acute exacerbation of IPF) will be 
analysed using a Cox proportional hazards model with covariates treatment, baseline FVC (mL) 
along with any other covariates included in the analysis of the primary endpoint . The equality of 
the hazard rates between the GB0139 3mgand placeb o group will be tested by the Wald test for 
the treatment effect. The model will include treatment as covariates. Breslow’s method for 
handling ties will be used. Kaplan -Meier plots by treatment group will also be presented. 
Time to death from all causes (plus death from respiratory- related causes if numbers allow ) will 
be analysed using a Cox proportional hazards model. The equality of the hazard rates between 
the GB0139 3mggroup and placebo will be tested by the Wald test for the treatment effect. The 
model will include treatment, baseline FVC (mL) as covariates along with any other covariates 
included in the analysis of the primary endpoint . Breslow’s method for handling ties will be 
used. Kaplan- Meier plots by treatment group will also be presented. I f the proportion of deaths is 
less than 5%, then only frequencies of deaths by treatment group will be provided for the key 
secondary endpoint of time todeath and no statistical analysis will be performed.    
Galecto Biotech AB Page 62 of 105
GALACTIC -1 v7.1_UK 28 January 2022
14.4.2.2 Other Secondary Endpoints
All further endpoi nt analyses will be considered exploratory in nature. 
Data will be summarized graphically and using summary statistics. 
Any p -values presented for the secondary endpoints will be considered nominal in nature and no 
adjustment for multiplicity will be mad e. 
Further details are given in the SAP.
Secondary Efficacy Analysis
Secondary efficacy analysis of subgroups will be based on :
Strata (i .e.analysing available data from SoC1)
Previous treatment with pirfenidone and/or nintedanib
Cohort ( e.g.pre-or post -DSMB cutoff, and pre -or post -Protocol version 6. 1_UK)
The same endpoints as for the primary and key secondary efficacy analysis will be analysed in an 
exploratory manner with the same methods as described for the primary efficacy analysis. No 
formal statistical hypotheses will be tested.
14.5.1 Other Analyses
Intervention groups should be compared on baseline characteristics, including demographics and 
laboratory measurements, using descriptive statistics. No inferential statistics will be used. The 
primary and key secondary endpoints will be analysed by age, gender, race and ethnicity. Models 
as described for the primary and key secondary endpoints will be used in cluding the covariates 
defining the subgroup in the model and a covariate -by-treatment interaction factor. Individual 
subject data will be listed by treatment group and time point.
14.5.2 Safety Analysis
The primary assessment of benefit -risk of GB0139 3mg compared to Plc will be based on 
efficacy and safety data over 52 weeks. All safety assessments described below will focus on 14.5
Galecto Biotech AB Page 63of 105
GALACTIC -1 v7.1_UK 28 January 2022
data collected within the first 52 weeks of the study. In addition, selected safety analyses will be 
repeated to include data collected beyond 52 weeks; further details will be specified in the SAP. 
All treated subjects will be included in the safety analysis. The primary safety assessment will be 
based on the participants who received 3mg or placebo as study treatments.  A sep arate safety 
assessment will be made for the participants who received study treatment in combination of 
nintedanib or pirfenadone. The particular tables and figures to be split in this way will be 
specified in the SAP. In general, safety analyses will be descriptive in nature. No hypothesis 
testing is planned. 
Kaplan -Meier plots will be produced for the time to premature treatment discontinuation. 
Statistical analysis and reporting of adverse events will concentrate on treatment -
emergent 
adverse events. A ll adverse events occurring between start of treatment and end of the residual 
effect period will be considered ‘treatment -emergent’. The residual effect period is defined as the 
28 days after the date of the last dose of trial medication. Adverse events t hat start before first 
drug intake and deteriorate under treatment will also be considered ‘treatment -emergent’. 
Frequency, severity, and causal relationship of adverse events will be tabulated by system organ 
class and preferred term after coding accordin g to the current version of MedDRA. 
Laboratory data will be analysed both quantitatively as well as qualitatively. The latter will be 
done via comparison of laboratory data to their reference ranges. Values outside the reference 
range as well as values de fined as clinically relevant will be highlighted in the listings. Treatment 
groups will be compared descriptively with regard to distribution parameters as well as with 
regard to frequency and percentage of subjects with abnormal values or clinically relev ant 
abnormal values. 
Vital signs, physical examinations, or other safety -relevant data observed at screening, baseline, 
during the course of the treatment and at the end -of-treatment evaluation will be assessed with 
regard to possible changes compared to findings before start of treatment.
Galecto Biotech AB Page 64 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Determination of Sample Size
The null hypothes is for the treatment difference between GB0139 at 3mg and placebo for the 
two doses is tested using a type I error of 10% for a 2 -side test . The power for detecting a 
statis ticallysignificant difference in the treatment effect (annual rate of decline in FVC or the 
FVC change from baseline to 52 weeks) is dependent on the effect size (mean treatment 
difference/ standard deviation) and the number of subjects per treatment grou p.
To detect an average difference from placebo in decline in FVC of at least 100 ml and with a 
standard deviation of 240 ml then a final sample size of 141subjects would provide 75% power, 
assuming that future subjects are randomised into the study on a 1:2 randomisation allocation so 
that for every subject randomised to placebo 2 subjects will be randomised to 3 mg GB0139 .
Randomization
Following the Protocol version 6. 1_UK participants will be randomised in blocks to double- blind 
treatment in a 1:2 ratio (Placebo : GB0139 3mg). The unbalanced randomisation is to maintain 
the same probability of allocation to placebo post -Protocol version 6. 1_UK since this may 
impact participant enrolment. Note that prior to Protocol version 6. 1_UK participants were
randomized in blocks to double -blind treatment in a 1:1:1 ratio ( GB0139 3mg: GB0139 10mg: 
Placebo) stratified by SoC . 
The Sponsor will arrange for the randomization and the packaging and labelling of trial
medication. The randomization list will be generated using a validated system, which involves a 
pseudo -random number generator so that the resulting treatment will be both reproducible and 
non-predictable. The block size will be documented in the CTR. Acc ess to the codes will be 
controlled and documented.
Handling of Missing Data
This section describes the estimands approach for the primary analysis and associated sensitivity 
analyses using the Detailed Clinical Objectives framework described by Bell [51].14.6
14.7
14.8
Galecto Biotech AB Page 65of 105
GALACTIC -1 v7.1_UK 28 January 2022
The trial will compare GB0139 3 mg with Placebo in patients with IPF not currently treated with 
pirfenidone or nintedanib. The primary objective is to demonstrate superiority of GB0139 3 mg 
for the mean annual rate of decl
ine in FVC in mL. A composite strategy will be taken to patient 
deaths with FVC attributed the lowest value recorded in the trial when a patient dies.
Three specific inter -current events (ICEs) are anticipated during the trial: death, treatment 
discontinua tion, and initiation of pirfenidone or nintedanib. The handling of these ICEs for the 
treatment effect of primary interest and planned sensitivity analyses for the primary endpoint are 
described in Table 5.
Table 5: Handling of anticipated ICEs for treatment effect of primary endpoint
Treatment 
effectDescription Death Treatment 
discontinuationInitiation of IPF 
therapy
Primary (ICEs 
of treatment 
discontinuation 
or additional 
IPF therapy)Randomized and 
treated patients 
with treatment 
policy applied 
for intercurrent 
events other than 
deathFVC attributed 
the lowest 
value recorded 
in the trial 
when a patient 
diesAnalysis will include 
all available FVC 
measurements after 
randomised treatment 
discontinuationAnalysis will include 
all available FVC 
measurements after 
initiation of additional 
IPF therapy
Sensitivity 1 
(on-treatment)Randomized and 
treated patients 
while on 
randomised 
treatmentFVC attributed 
the lowest 
value recorded 
in the trial 
when a patient 
diesAnalysis will exclude 
any FVC 
measurements after 
randomised treatment 
discontinuationAnalysis will exclude 
any FVC 
measurements after 
initiation of additional 
IPF therapy
Sensitivity 2 
(ICE of Death)Randomized and 
treated patients 
while on FVC attributed 
value of 0 Analysis will exclude 
any FVC 
measurements after Analysis will exclude 
any FVC 
measurements after 
Galecto Biotech AB Page 66of 105
GALACTIC -1 v7.1_UK 28 January 2022
randomised 
treatmentwhen a patient 
diesrandomised treatment 
discontinuationinitiation of additional 
IPF therapy
Sensitivity 3 
(Tipping point 
for ICE of 
Death will only 
be performed if 
sensitivity 2 
indicates a 
different 
conclusion to 
primary 
analysis)Randomized and 
treated patients 
while on 
randomised 
treatmentWhen a patient 
dies FVC 
attributed a 
series of values 
between 0 and 
the lowest 
value recorded 
in the trial Analysis will exclude 
any FVC 
measurements after 
randomised treatment 
discontinuationAnalysis will exclude 
any FVC 
measurements after 
initiation of additional 
IPF therapy
Further details for the tipping point analysis can be found in the SAP.
Galecto Biotech AB Page 67 of 105
GALACTIC -1 v7.1_UK 28 January 2022
15.0 QUALITY CONTROL AND QUALITY ASSURANCE
Study -Site Monitoring Visits
Monitoring visits to the study site will be done periodically during the study to ensure that all 
aspects of the protocol are followed, and according to the monitoring plan. Source documents 
will be reviewed for verification of data recorded on the eCRFs. Source documents are defined 
as original documents , data, and records. The investigator and institution guarantee access to 
source documents by the sponsor or its designee (CRO) and by the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or 
designee (as l ong as blinding is not jeopardized), including but not limited to the Investigator’s 
Binder, study medication, subject medical records, informed consent documentation, 
documentation of subject authorization to use personal health information (if separate f rom the 
informed consent forms), and review of eCRFs and associated source documents. It is important 
that the investigator and delegated study personnel are available during the monitoring visits and 
that sufficient time is devoted to the process.
Protoco l Deviations
The investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will 
require deviation from protocol -specified procedures, the i nvestigator should consult with the 
sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of action. 
There will be no exemptions (a prospectively approved deviation) from the inclusion or 
exclusion criteria.
The site must do cument all protocol deviations in the subject’s source documents. In the event of 
a significant deviation, the site must notify the sponsor or its designee (and IRB or EC, as 
required). Significant deviations include, but are not limited to, those that inv olve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. Protocol Deviations are recorded by the CRO's CRA in their clinical trial 15.1
15.2
Galecto Biotech AB Page 68 of 105
GALACTIC -1 v7.1_UK 28 January 2022
management system. All recorded Protocol Deviations will be shared with the investigator in 
writing following each monitoring visit, and period reports will be made available as required for 
submission to the EC/IRB . Recorded Protocol Deviations will also be reviewed regularly with 
Galecto .
The investigator can de viate and change from the protocol for any medically unavoidable reason, 
for example, to eliminate an immediate hazard to study subjects, without a prior written 
agreement from the sponsor or a prior approval from IRB. In the event of a deviation or change , 
the principal investigator should notify the sponsor and the head of the site of the deviation or 
change as well as its reason in a written form, and then retain a copy of the written form. When 
necessary, the principal investigator may consult and agree with the sponsor on a protocol 
amendment. If the protocol amendment is appropriate, the amendment proposal should be 
submitted to the head of the site as soon as possible and an approval from IRB should be 
obtained.
The investigator must document all protocol deviations.
Quality Assurance Audits and Regulatory Agency Inspections
The study site also may be subject to quality assurance audits by the sponsor or designees. In this 
circumstance, the sponsor -designated auditor will contact the site in advance to arrange an 
auditing visit or remote auditing. The auditor may ask to visit the facilities where laboratory 
samples are collected, where the medication is stored and prepared, and any other facility used 
during the study. In addition, there is th e possibility that this study may be inspected by 
regulatory agencies, including those of foreign governments (e.g., the FDA, the United Kingdom 
Medicines and Healthcare products Regulatory Agency). If the study site is contacted for an 
inspection by a reg ulatory body, the sponsor should be notified immediately. The investigator 
and institution guarantee access for quality assurance auditors to all study documents as 
described in Section 15.1.15.3
Galecto Biotech AB Page 69 of 105
GALACTIC -1 v7.1_UK 28 January 2022
16.0 ETHICAL ASPECTS OF THE STUDY
This study will be conducted with the highest respect for the individual subjects (i.e., subjects) 
according to the protocol, the ethical principles that have their origin in the De claration of 
Helsinki, and the ICH Harmonised Tripartite Guideline for GCP. Each investigator will conduct 
the study according to applicable local or regional regulatory requirements and align his or her 
conduct in accordance with the “Responsibilities of the Investigator” that are listed in Section 
18.0. The principles of Helsinki are addressed through the protocol and through appendices 
containing requirements for in formed consent and investigator responsibilities.
IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable requirements of each 
participating region. The sponsor or designee will require documentation noting all names and 
titles of members who make up the respective IRB or IEC. If any member of the IRB or IEC has 
direct participation in this study, written notification regarding his or her abstinence from voting 
must also be obtained. Those American sites unwilling to provide na mes and titles of all 
members due to privacy and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Investigator’s Brochure, a copy of 
the informed consent form, and, if applicable, subject recruitment materials and/or 
advertisements and othe r documents required by all applicable laws and regulations, must be 
submitted to a central or local IRB or IEC for approval. The IRB’s or IEC’s written approval of 
the protocol and subject informed consent must be obtained and submitted to the sponsor or 
designee before commencement of the study (i.e., before shipment of the sponsor -supplied drug 
or study specific screening activity). The IRB or IEC approval must refer to the study by exact 
protocol title, number, and version date; identify versions of oth er documents (e.g., informed 
consent form) reviewed; and state the approval date. Once the sponsor or designee has confirmed 16.1
Galecto Biotech AB Page 70 of 105
GALACTIC -1 v7.1_UK 28 January 2022
the adequacy of site regulatory documentation and, when applicable, the sponsor or designee has 
received permission from competent authority to begin the trial, it will notify investigative sites 
meaning that protocol activities and screening may occur.
Sites must adhere to all requirements stipulated by their respective IRB or IEC. This may include 
notification to the IRB or IEC rega rding protocol amendments, updates to the informed consent 
form, recruitment materials intended for viewing by subjects, local safety reporting requirements, 
reports and updates regarding the ongoing review of the study at intervals specified by the 
respec tive IRB or IEC, and submission of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
sponsor or its designee.
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody the elements of informed consent as described in the 
Declarati on of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form describes the planned and permitted 
uses, transfers, and disclosures of the subject’s personal health information fo r purposes of 
conducting the study. The informed consent form further explains the nature of the study, its 
objectives, and potential risks and benefits, as well as the date informed consent is given. The 
informed consent form will detail the requirements of the subject and the fact that he or she is 
free to withdraw at any time without giving a reason and without prejudice to his or her further 
medical care.
The designated CRO s are responsible for the preparation, content, and IRB or IEC approval of 
the informed consent form. The informed consent form must be approved by both the IRB or 
IEC and the sponsor prior to use.16.2
Galecto Biotech AB Page 71of 105
GALACTIC -1 v7.1_UK 28 January 2022
The informed consent form must be written in a language fully c omprehensible to the 
prospective subject. It is the responsibility of the investigator to explain the detailed elements of 
the informed consent form to the subject. Information should be given in both oral and written 
form whenever possible and in the mann er deemed appropriate by the IRB or IEC. In the event 
the subject is not capable of rendering adequate written informed consent, then the subject’s 
legally acceptable representative may provide such consent for the subject in accordance with 
applicable law s and regulations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity 
to: (1) inquire about details of the study and (2) decide whether or not to participate in the study. 
If the subject, or the subject’s legal ly acceptable representative, determines he or she will 
participate in the study, then the informed consent form must be signed and dated by the subject, 
or the subject’s legally acceptable representative, at the time of consent and prior to the subject 
entering into the study. The subject or the subject’s legally acceptable representative should be 
instructed to sign using their legal names, not nicknames, using blue or black ballpoint ink. The 
investigator must also sign and date the informed consent form at the time of consent and prior to 
subject entering into the study; however, the sponsor may allow a designee of the investigator to 
sign to the extent permitted by applicable law.
Once signed, the original informed consent form will be stored in the inv estigator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form shall be given to the subject.
All revised informed consent forms must be revi ewed and signed by relevant subjects or the 
relevant subject’s legally acceptable representative in the same manner as the original informed 
consent. The date the revised consent was obtained should be recorded in the subject’s medical 
record, and the subj ect should receive a copy of the revised informed consent form.
Galecto Biotech AB Page 72 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Subject Confidentiality
The sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy. Throughout this study, a subject’s source da ta will only be linked to 
the sponsor’s clinical study database or documentation via a unique identification number. As 
permitted by all applicable laws and regulations, limited subject attributes, such as sex, age, or 
date of birth, and subject initials m ay be used to verify the subject and accuracy of the subject’s 
unique identification number.
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the 
sponsor requires the investigator to permit its monitor or designee’s monito r, representatives 
from any regulatory authority (e.g., FDA, Medicines and Healthcare products Regulatory 
Agency, Pharmaceuticals and Medical Devices Agency), the sponsor’s designated auditors, and 
the appropriate IRBs and IECs to review the subject’s orig inal medical records (source data or 
documents), including, but not limited to, laboratory test result reports, ECG reports, admission 
and discharge summaries for hospital admissions occurring during a subject’s study 
participation, and autopsy reports. Ac cess to a subject’s original medical records requires the 
specific authorization of the subject as part of the informed consent process (see Section 16.2).
Copies of any subject source documents that are provided to the sponsor must have certain 
personally identifiable information removed (i.e., subject name, address, and other identifier 
fields not collected on the subject’s eCRF).
Publication, Disclos ure, and Clinical Trial Registration Policy
16.4.1 Publication 
The investigator is obliged to provide the sponsor with complete test results and all data derived 
by the investigator from the study. During and after the study, only the sponsor may make study 
information available to other study investigators or to regulatory agencies, except as required by 
law or regulation. Except as otherwise allowable in the clinical study site agreement, any public 16.3
16.4
Galecto Biotech AB Page 73 of 105
GALACTIC -1 v7.1_UK 28 January 2022
disclosure (including publicly accessible websites) related to the protocol or study results, other 
than study recruitment materials and/or advertisements, is the sole responsibility of Galecto.
The sponsor may publish any data and information from the study (including data and 
information generated by the investigator) without the consent of the investigator. Manuscript 
authorship for any peer -reviewed publication will appropriately reflect contributions to the 
production and review of the document. All publications and presentations must be prepared in 
accordance wi th this section and the Clinical Study Site Agreement. In the event of any 
discrepancy between the protocol and the Clinical Study Site Agreement, the Clinical Study Site 
Agreement will prevail.
16.4.2 Clinical Trial Registration
In order to ensure that informati
on on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulations and guidance, Galecto will, at a minimum register 
interventional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov or other 
publicly accessible websites on or before start of study . Galecto contact information, along with 
investigator’s city, state (for Americas investigators), country, and recruiting status will be 
registered and available for public viewing. 
As needed Galecto and Investigator/site contact information may be made public to support 
subject access to trials via registries. Once subjects receive investigator contact information, they 
may call the site requesting enrollment into the trial. The inve stigative sites are encouraged to 
handle the trial inquiries according to their established subject screening process.
16.4.3 Clinical Trial Results Disclosure
Galecto Biotech will post the results of clinical trial son ClinicalTrials.gov or other publicly 
access ible websites (including the Galecto corporate site) and registries. 
Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the 
site where the subject is participating. If a local u nderwriter is required, then the sponsor’s 16.5
Galecto Biotech AB Page 74of 105
GALACTIC -1 v7.1_UK 28 January 2022
designee will obtain clinical study insurance against the risk of injury to clinical study subjects. 
Refer to the Clinical Study Site Agreement regarding the sponsor’s policy on subject 
compensation and treatment for injury. If the investigator has questions regarding this policy, he 
or she should contact the sponsor or sponsor’s designee.
Galecto Biotech AB Page 75of 105
GALACTIC -1 v7.1_UK 28 January 2022
17.0 REFERENCES
1. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, 
Hansell DM, Inoue Y, Johkoh T, Nic holson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, 
Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society 
White Paper. Lancet Respir Med. 2018;138 -
1532.
2. American Thoracic Society/European Respiratory Society. International multidisciplinary 
consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 
2002; 165:277 −304.
3. Raghu G, Collard HR, Egan J, et al. An official ATS/ERS/JRS/ALAT statement: 
idiopathic pulmonary fibrosis: evidence -based guidelines for diagnosis and management. Am J 
Respir Crit Care Med 2011; 183:788–824.
4. Kim HJ, Perlman D, Tomic R. Natural history of idiopathic pulmonary fibrosis. Respir 
Med 2015;109:661–70.
5. King TE Jr, Tooze JA, SchwarzMI, Brown K, C herniack RM. Predicting survival in 
idiopathic pulmonary fibrosis. Scoring system and survival model. Am J Respir Crit Care  Med 
2001; 164:1171 –1181.
6.
Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, 
Veeraraghavan S, Hansel l DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the  
prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531 –
537.
7. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic 
pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:431 –440.
8.
Talmadge E King Jr, Annie Pardo, Moisés Selman. Idiopathic Pulmonary Fibrosis. 
Lancet  2011; 378:1949 –61.
9. Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, Snead A, Lu D,and 
Aroonsakool N. cAMP and Epac in the regulation of tissue fibrosis. Br J Pharmacol 2012; 
166:447
–456.
10. Friedman SL, Sheppard D, Duffield JS, and Violette S. Therapy for fibrotic disea ses: 
nearing the starting line. Sci Transl Med 2013; 5:167sr1.
11. Speca S, Giusti I, Rieder F, and Latella G. Cellular and molecular mechanisms of 
intestinal fibrosis. World J Gastroenterol 2012; 18:3635 –3661.
12. Kuhn C III, Boldt J, King TE Jr, Crouch E , Vartio T, McDonald JA. An  
immunohistochemical study of architectural remodeling and connective tissue synthesis in  
pulmonary fibrosis. Am Rev Respir Dis 1989; 140(6):1693
–1703
13. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 201 1; 
378(9807):1949- 1961. 
Galecto Biotech AB Page 76of 105
GALACTIC -1 v7.1_UK 28 January 2022
14. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, SheppardD, 
and Chapman HA. Alveolar epithelial cell mesenchymal transition develops in vivo during 
pulmonary fibrosis and is regulated by the extracellular mat
rix. Proc Natl Acad Sci USA 2006; 
103:13180–13185.
15. Sureshbabu A, Tonner E, Allan GJ, and Flint DJ. Relative roles of TGF -b and IGFBP -5 
in idiopathic pulmonary fibrosis. Pulm Med 2011:517687.
16. Kurotsu S, Tanaka K, Niino T, Asano T, Sugizaki T, Azuma A, Suzuki H, and 
Mizushima T. Ameliorative effect of mepenzolate bromide against pulmonary fibrosis. J 
Pharmacol Exp Ther 2014; 350:79–88.
17. Wollin L, Maillet I, Quesniaux V, Holweg A, and Ryffel B. Antifibrotic and  
antiinflammatory activity of the tyro sine kinase inhibitor nintedanib in experimental models of 
lung fibrosis. J Pharmacol Exp Ther 2014; 349:209–220.
18.
Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson 
AJ, Forbes SJ, Hirani N, and Gauldie J, et al. Regulatio n of transforming growth factor b1- driven 
lung fibrosis by galectin- 3. Am J Respir Crit Care Med 2012; 185:537 -546.  
19. Kasper M and Hughes RC. Immunocytochemical evidence for a modulation of galectin 3 
(Mac -2), a carbohydrate binding protein, in pulmona ry fibrosis. J Pathol 1996; 179:309–316.
20. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that 
inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab  1998; 
83(1):219 –223.
21. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and 
prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin -induced 
murine pulmonary fibrosis. Eur J Pharmacol 2008; 590(1 –3):400 –408.
22. Iyer SN, Guruj eyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth 
factor -beta gene expression at the transcriptional level in bleomycin hamster model of lung  
fibrosis. J Pharmacol Exp Ther 1999; 291(1):367–373.
23. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene 
expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J  Pharmacol 
Exp Ther 1999; 289(1):211 –218.
24.
Copley SJ, Wells AU, Hawtin KE, et al. Lung morphology in the elderly: comparati ve 
CT  study of subjects over 75 years old versus those under 55 years old. Radiology 2009; 251: 
566–573.
25. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in  
smokers with interstitial lung abnormalities. N Engl J Med 2011; 36 4:897 –906.
26. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic  
pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:431 –440.
Galecto Biotech AB Page 77of 105
GALACTIC -1 v7.1_UK 28 January 2022
27.
Ryerson CJ, Cottin V, Brown KK, et al. Acute exacerbation of idiopathic pulmonary 
fibrosis: shifting the paradigm. Eur Respir J 2015; 46:512 –520.
28. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary  
fibrosis. Am J Respir Crit Care Med 2007; 176:636
–643.
29. Martinez FJ, Safrin S, Weycker D, et al. Th e clinical course of subjects with idiopathic   
pulmonary fibrosis. Ann Intern Med 2005; 142:963
–967.
30. Swigris JJ, Gould MK, Wilson SR. Health
-related quality of life among subjects with  
idiopathic pulmonary fibrosis. Chest 2005; 127:284 –294.
31.
Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin 
Invest 2012; 122:2756 –2762.
32.
Borie R, Justet A, Beltramo G, Manali ED, Pradere P, Spagnalo P, Crestani B. 
Respirology 2016; 21(4):615- 625. 
33. Richeldi L, du Bois R M, Raghu G, et al; INPULSIS Trial Investigators. Efficacy and 
safety  of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2071 –2082.
34.
Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfenidone in  
subjects with idiop athic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 
377(9779):1760–1769.
35. King TE Jr, BradfordWZ, Castro- Bernardini S, et al; ASCEND Study Group. A phase 3  
trial of pirfenidone in subjects with idiopathic pulmonary fibrosis. N Engl J Med 2014; 
370(22):2083 –2092.
36. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice 
guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical  practice 
guideline. Am J Respir Crit Care Med 201 5; 192:e3 –19.  
37. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of 
management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014; 2:933 –942.
38. Collard HR, Bradford WZ, Cottin V, et al. A new era in idiopathic pulmonary fibrosis: 
considerations for future clinical trials. Eur Respir J 2015; 46:243 –249.
39. Wells A. Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be 
hard. Eur Respir J 2015; 45:1208
–1210.
40. Richeldi L, Davies HR, Ferrara G, e t al. Corticosteroids for idiopathic pulmonary 
fibrosis.     Cochrane Database Syst Rev. 2003; 3:CD002880.
41. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary 
fibrosis. Cochrane Database Syst Rev. 2003; 3:CD003134.
42. D umic, J., S. Dabelic, and M. Flogel, Galectin -3: an open -ended story. Biochim Biophys 
Acta, 2006. 1760(4): p. 616
-35.
Galecto Biotech AB Page 78of 105
GALACTIC -1 v7.1_UK 28 January 2022
43. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, et al.., 
Regulation of transforming growth factor
-beta1 -driven lung fibrosis by galectin-3. Am J Respir 
Crit Care Med, 2012. 185(5): p. 537-46.
44. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al 
Galectin
-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A, 
2006. 103(13): p. 5060-5.
45. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. 
Galectin
-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis. Am 
J Pathol, 2008. 172(2): p. 288 -298.
46. Farnworth SL, Henderson NC, Mackinnon AC, Atkinson KM, Wilkinson T, Dhaliwal K, 
et al., Galectin -3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil 
function. Am J Pathol, 2008. 172(2): p. 395 -
405.
47. Dang Z, MacKinnon A, Marson LP, & Se thi T. Tubular atrophy and interstitial fibrosis 
after renal transplantation is dependent on galectin -3. Transplantation, 2012. 93(5): p. 477-84.
48. MacKinnon AC, Liu X, Hadoke PW, Miller MR, Newby DE, & Sethi T. Inhibition of 
galectin -3 reduces atheroscl erosis in apolipoprotein E -deficient mice. Glycobiology, 2013. 23(6): 
p. 654 -
63
49. Delaine T, Collins P, MacKinnon A, Sharma G, Stegmayr J, Rajput VK, et al. (2016). 
Galectin
-3-Binding Glycomimetics that Strongly Reduce Bleomycin -Induced Lung Fibrosis and
Modulate Intracellular Glycan Recognition. Chembiochem : a European journal of chemical 
biology 17: 1759 -1770.
50. Hirani, H., MacKinnon, A.C., Nicol, L., Ford, P., Schambye, H., Pedersen, A., Nilsson,
U.J., Leffler, H., Sethi, T., Tantawi, S., Gavelle, L., Slack, R.J., Mills, R., Karmakar, U.,
Humphries, D., Zetterberg, F., Keeling, L., Paul, L., Molyneaux, P.L., Li, F., Funston, W.,
Forrest, I.A., Simpson, A.J., Gibbons, M., Maher, T.M., 2020. Target -inhibition of Galectin -3 by
Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis. Eur J Respir (in press).
51.Bell J,Hamilton A, Sailer O, Voss F. The detailed clinical objectives approach to designing
clinical trials and choosing estimands . Pharmaceutical Statistics. 2021;1–13.
Galecto Biotech AB Page 79 of 105
GALACTIC -1 v7.1_UK 28 January 2022
18.0 APPENDICES
Appendix 1. Plastiape DPI Inhaler Device -Instructions for Use
1. Remove the protective cap from the 
Plastiape inhaler.
2. Open mouthpiece to access
the capsule housing.
3. Peel back foil from the 
blister strip and remove 
capsule from the blister. 
18.1
Galecto Biotech AB Page 80 of 105
GALACTIC -1 v7.1_UK 28 January 2022
4. Load capsule into housing and then shut 
the mouthpiece.
5. Pierce the capsule:
• Hold the inhaler upright with the mouthpiece 
pointing up.
• Pierce the capsule by firmly pressing together 
both side buttons at the same time. Do this 
only once.
• You should hear a “click” as the capsule is being pierced.
6. Breathe out:
Before placing the mouthpiece in your mouth, breathe out fully and donot blow into the 
mouthpiece .

Galecto Biotech AB Page 81 of 105
GALACTIC -1 v7.1_UK 28 January 2022
7. Inhalation
To breathe the medicine deeply into your 
airways:
• hold the inhaler so the side buttons are facing 
left and right, and do not press the side buttons.
• place the mouthpiece in your mouth and close 
your lips firmly around it.
• breathe in rapidly but steadily and as deeply as they can.
8. Note:
As you breathe in through the inhaler, the capsule spins around in the chamber and you should  
hear a whirring noise . 
9. Breath hold:
After you have in haled the medicine:
• 
Hold your breath for at least 5 -10 seconds or as long as you comfortably can. 
• Then breathe out. Open the inhaler to see if any powder is left in the capsule.
If there is powder left in the capsule:
• Close the inhaler.
• Repeat steps 6 to 9 (second inhalation)

Galecto Biotech AB Page 82of 105
GALACTIC -1 v7.1_UK 28 January 2022
If there is powder left in the capsule:
• Close the inhaler.
• Repeat steps 6 to 9 (third inhalation)
Most people are able to empty the capsule with one or two inhalations, but a maximum of 3 
inhalations can be pe rformed. Please note that 2 capsules are used per dose so steps 3 -10 are 
repeated with the second capsule. 
Please ensure you return all unused medication to your study staff at each visit, including all 
blister packs. 
Please ensure you contact study staf
f if you have further questions. You will receive training 
prior to your first drug administration by a member off your clinical team. Please ask any 
questions to your study throughout the study, as required. 
Galecto Biotech AB Page 83 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Appendix 2. Biomarker Panel
Biomarkers have the potential to impact all aspects of the clinical care of IPF patients including 
diagnosis and prognosis. The identification of serum biomarkers that are diagnostic for IPF would 
be helpful for both clinicians and patients, particularly in cases where a surgical lung biopsy had 
not been obtained or access to dedicated interstitial lung disease/IPF physicians is limited. 
Secondly, the discovery of peripheral blood biomarkers that reflect disease activity would allow 
for serial monitoring as well as an objective marker to assess treatment efficacy. Lastly, a 
biomarker that provides prognostic information about disease course and/or mortality would be 
valuable for both clinical care and future research study design.
In the context of Galactic -1 study a number of serum biomarkers will be explored:
These may includ ebut are not limited to YKL -40, PAI -1, PDGF -BB, MCP -1, CCL -18, KL -6, 
CA-125, CA -19, Gal-3and collagen neoepitopes. Testing will be performed at time points 
indicated in the Time and Events Table.
Galectin - 3
Galectins are a group of soluble β -galactoside -binding lectins that play many important regulatory 
roles in inflammation, immunologic response and cancer. A total of 15 galectins have been 
identified. Galectin -3 is the most widely studied member of the galectin protein family [ 1, 2].
Galectin- 3 is a mid-size protein (29 to 35 kDa) consisting of an N-terminal domain with tandem 
repeats of short amino acid segments (a total of approximately 120 amino acids) linked to a single 
C-terminal carbohydrate -recognition domain (CRD) of about 130 amino acids. It can interact with 
carbohydrates, which involves the C-terminal domain, and with unglycosylated molecules, such 
as ce ll surface and extracellular receptors, which involves the N -terminal domain [ 3].
As other galectins, galectin -3 does not contain a signal sequence, therefore it is localized primarily 
in the cytoplasm, and occasionally, in the nucleus and mitochondria. Galectin- 3 is found in 
epithelial cells, fibroblasts, dendritic cells and inflammatory cells. In addition, galectin- 3 can be 18.2
Galecto Biotech AB Page 84of 105
GALACTIC -1 v7.1_UK 28 January 2022
secreted and function in extracellular space. It can form pentamers upon binding to multivalent 
carbohydrates, therefore it is capabl e of crosslinking glycans on the cell surface, and in this manner 
initiating transmembrane signaling events and affecting various cellular functions [ 4].
Galectin
-3 is known for its role in tumorigenesis and progression through regulating cell 
proliferation, apoptosis, cell adhesion, invasion, angiogenesis and metastasis. Expression of 
galectin -3 is modulated in many different cancers. Measurement of serum galectin -3 can be helpful 
in diagnosis and prognosis for specific cancer types, such as th yroid and prostate [ 5].
One of the more interesting and well characterized effects is the role of galectin -3 in the promotion 
of fibrosis. Fibrogenesis or scarring is a consequence of certain types of injury and inflammation, 
which are central pathophysiol ogical mechanisms in the development and progression to heart 
failure. Expression of galectin -3 is low in a healthy human heart; however, as heart failure 
progresses galectin -3 becomes significantly up-regulated. It is released by activated cardiac 
macroph
ages stimulating additional macrophages, pericytes, myofibroblasts, and fibroblasts, 
which in response signal cellular proliferation and secretion of procollagen I. Procollagen I 
irreversibly crosslinks to form collagen and results in cardiac fibrosis [ 6 -10].
Involvement of galectin -
3 in fibrosis has also been demonstrated in liver [ 11] and kidney [ 12].
Inhibition of galectin -3 appears to prevent progression of fibrosis. Recent publications describe 
the tetrapeptide, N -acetyl -seryl -aspartyl -lysyl -proline ( Ac-SDKP) that causes inhibition of cardiac 
fibroblast proliferation and collagen synthesis. Ac-SDKP is a naturally occurring anti-
inflammatory and antifibrotic peptide that is hydrolyzed almost exclusively by angiotensin-
converting enzyme (ACE), and plasma concentration of Ac-SDKP is increased substantially by 
ACE inhibitors. Rats overexpressing cardiac ACE have decreased Ac-SDKP concentration and 
increased fibrosis in heart tissue [13]. Other studies include galectin -3 knock -out mice, use of small 
interfer ing RNA that can silence galectin -3 gene activity and use of carbohydrate molecules, which 
can deactivate galectin -3.
Galecto Biotech AB Page 85of 105
GALACTIC -1 v7.1_UK 28 January 2022
Because of the unambiguous association of galectin -3 with the disease development, progression 
and poor outcome, measurement of galectin -
3in patients diagnosed with IPF, pulmonary 
hypertension, acute and chronic heart failure may have diagnostic and therapeutic implications.
Recently, the FDA has approved for market an assay manufactured by BG Medicine, Inc. 
(Waltham, MA) for galectin -3 to supplement standard risk assessment in patients with chronic 
heart failure [ 14]. BGM Galectin -3 is currently available at Pacific Biomarkers. The test is based 
on the common ELISA utilizing two monoclonal antibodies against galectin -3. One rat monoclonal 
anti-mouse galectin -
3 antibody is coated onto the surface of wells as a capture antibody to bind 
galectin -3 molecules in samples, while the other mouse monoclonal anti-human galectin -3 
antibody is provided in solution and functions as the tracer antibody for detecting galectin -3 
molecules bound to the capture antibody [ 15].
Galectin
-3 results should be interpreted with caution. Levels may be increased in patients with 
certain forms of cancer, in other conditions associated with organ fibrosis, and in patient s with a 
history of therapeutic use of murine monoclonal antibodies (IgG) or fragments, or who have known 
autoimmune disorders. Additionally, specimens with high levels of gamma globulins (>2.5 g/dL) 
may cause false elevation in results.
References:
1. Bar ondes SH, Castronovo V, Cooper DN, et al. A family of animal beta -galactoside -binding 
lectins. Cell. 1994; 76:597 - 8.
2. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic 
potential. Expert Rev Mol Med . 2008; 13:e17- e39.
3. Barboni EA, Bawumia S, Henrick K, and Hughes RC. Molecular modeling and mutagenesis 
studies of the N -terminal domains of galectin -3: evidence for participation with the C -terminal 
carbohydrate recognition domain in oligosaccharide binding. Glycobiology . 
2000; 10(11):1201 -8.
4. Ochieng J, Furtak V, and Lukyanov P. Extracellular functions of galectin-3. Glycoconj J . 
Galecto Biotech AB Page 86of 105
GALACTIC -1 v7.1_UK 28 January 2022
2004; 19(7-9): 527 - 35.
5. Balan V, Nangia -Makker P, and Raz A. Galectins as Cancer Biomarkers. Cancers 2010; 2:592 -
598.
6. de Boer RA, Yu L, van V eldhuisen DJ. Galectin -3 in cardiac remodeling and heart 
failure Curr Heart Fail Rep . 2010;7:1
-8.
7. de Boer RA, Voors AA, Muntendam P, et al. Galectin- 3: a novel mediator of heart failure 
development and progression Eur J Heart Fail. 2009; 11:811 - 17.
8. de Filippi CR, Felker GM. Galectin -3 in heart failure -linking fibrosis, remodeling, and 
progression US Cardiology . 2010; 7:67- 70
9. Lok D, van der Meer P, de La Porte PM, et al. Galectin -3, a novel marker of macrophage 
activity, predicts outcome in patients wi th stable chronic heart failure J Am Coll Cardiol . 
2007; 49:98A
10. Shah RV, Chen
-Tournoux AA, Picard MH, et al. Galectin -3, cardiac structure and function, 
and long -term mortality in patients with acutely decompensated heart failure Eur J Heart Fail . 
2010; 12:826 - 32.
11. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin- 3 regulates myofi broblast 
activation and hepatic fibrosis. Proc Natl Acad Sci . 2006; 103:5060 -65.
12. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin- 3 expression and secret ion 
links macrophages to the promotion of renal fibrosis. Am J Pathol . 2008; 172:288 - 98.
13. Liu H, D‘Ambrosio M, Liao T, et al. N -acetyl -seryl -aspartyl- lysyl -proline prevents cardiac 
remodeling and dysfunction induced by galectin -3, a mammalian adhesion/gr owth- regulatory 
lectin Am J Physiol Heart Circ Physiol . 2009; 296:H404 - 12.
14. McCullough P, Olobatoke A, Vanhecke TE. Galectin -3: a novel blood test for the evaluation 
and management of patients with heart failure. Rev Cardiovasc Med .  2011; 12:200 - 10
15. G alectin -3 Product Insert (US), BG Medicine, Inc. , March 2011.
Galecto Biotech AB Page 87of 105
GALACTIC -1 v7.1_UK 28 January 2022
YKL
-40
Several studies have demonstrated elevated levels of YKL -40, human chitinase -like glycoprotein, 
in the serum and BALF of IPF patients, with a significant correlation between its serum l evels and 
clinical parameters, including PaO2, DLCO, and serum concentrations of KL-6. Additionally, 
enhanced expression of YKL -40 protein was found in bronchiolar epithelial cells and alveolar 
macrophages adjacent to fibrotic lesions by immuno -histochemis try [1-4]. Although the detailed 
biological function of YKL -40 has not been fully elucidated, recent studies have shown that this 
glycoprotein has an important role in tissue remodelling processes leading to fibrosis. YKL -40 
potently promotes the growth of fibroblasts, endothelial cells, synovial cells, and chondrocytes [ 5-
7].
In the lung, a recent study showed elevated serum YKL
-40 levels in patients with severe asthma, 
and its levels correlated with thickening of the subepithelial basement membr ane and pulmonary 
function [5, 6]. Taken together, these findings suggest that, besides etiology, YKL -40 can be 
increased under pathological conditions leading to chronic inflammation and tissue remodelling in 
the lung. Collectively, these data suggest that increased production of YKL -40 in IPF lungs 
contributes to tissue remodelling and fibrosis, possibly through its fibrogenic capacity [ 8-18]. 
References:
1. Furuhashi K, Suda T, Nakamura Y, et al. Increased expres sion of YKL -40, a chitinase -like 
protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med. 
2010; 104:1204 –1210. 
2. Korthagen NM, van Moorsel CH, Barlo NP, et al. Serum and BALF YKL -40 levels 
arepredictors of survival in idiopathic pulmonary fibrosis. Respir Med. 2011;105:1 06–113.
3.Korthagen NM, van Moorsel CH, Zanen P, Ruven HJ, Grutters JC. Evaluation of circulating 
YKL -40 levels in idiopathic interstitial pneumonias. Lung . 2014; 192:975 –980.
Galecto Biotech AB Page 88of 105
GALACTIC -1 v7.1_UK 28 January 2022
4.Chen G, Yang T, Gu Q, Ni XH, Zhao ZH, Ye J, Meng XM, Liu ZH, He JG, Xiong CM.
Elevated plasma YKL -
40 as a prognostic indicator in patients with idiopathic pulmonary 
arterial hypertension. Respirology 2014; 19:608 –615.
5.Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, 
Kiener P, Cullen M, Grandsaigne M, Dombret MC, Aubier M, Pretolani M, Elias JA.A 
chitinase -like protein in the lung and circulation of patients with severe asthma. N Engl J 
Med 2007; 357:2016 –2027.
6.Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J, Zhang T, Xiu Q. YKL -40 in asthmatic patients, 
and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur Respir J 
2010; 35:757 –760.
7.De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Patoureau P. YKL -40 
(Cartilage gp -39) induces proliferative events in cultured chondrocytes and synoviocytes and 
increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun
2001; 285:926e31.
8.American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. 
International consensus statement: American Thoracic Society and the European Respiratory 
Society. Am J Respir Crit Care Med 2000; 161:646e64.
9.Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase -like lectin, YKL -40, 
binds specifically to type I collagen and modulates the rate of type I collagen fibrilformation. 
J Biol Chem 2006; 281:21082e9.
10.Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL -40 concentrations in patients with 
rheumatoid arthritis: relation to disease activity. Rheumatology 1999; 38:618e26.
11.Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA, Graudal N. Increased 
serumYKL -
40 in patients with pulmonary sarcoidosis ea potential marker of disease 
activity? Respir Med 2005; 99:396e402.
Galecto Biotech AB Page 89 of 105
GALACTIC-1 v7.1_UK 28 January 2022
12. Kruit A, Grutters JC, Ruven HJ, Moors el CC, van den Bosch JM. A CHI3L1 gene 
polymorphismis associated with serumlevels of YKL-40, a novel sarcoidosis marker. Respir 
Med 2007; 101:1563e71.
13. Nordenbaek C, Johansen JS, Halberg P, et al. High serum levels of YKL-40 in patients with 
systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol
2005; 34:293e7.
14. Le´tuve´ S, Kozhich A, Arouche N, et al.  YKL-40 is elevated in patients with chronic 
obstructive pulmonary disease and activates alveolar macrophages. J Immunol
2008; 181:5167e73.
15. Furuhashi K, Suda T, Nakamura Y, et al. Increased expres¬sion of YKL-40, a chitinase-Like 
protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med.
2010; 104:1204–1210.
16. Korthagen NM, van Moorsel CH, Barlo NP, et al. Serum and BALF YKL-40 levels are 
predictors of survival in idiopathic pulmonary fibrosis. Respir Med. 2011; 105:106–113
KL-6/mucin 1 (MUC-1)
KL-6/mucin 1 (MUC-1) is a circulating glycoprotein belonging to the MUC-1 class and is
expressed on alveolar epithelial cells and bronchiolar epithelial cells. KL-6 exerts antifibrotic and
antiapoptotic effects on lung fibroblasts [ 1]. KL-6 is probably the most extensively studied serum 
biomarker in ILD, at least in Japan, where it has been used to assess patients in the clinical routine [2]. Serum KL-6 shows good correlation with disease severity, although it does not discriminate 
between different ILD patterns. Serum levels of KL-6 are significantly elevated in IPF and are 
associated with increased mortality. A serum cut-off value of ⩾1000 U·mL −1 has been associated 
with poor prognosis [3]. The presence of the MUC1 568 adenosine to guanine polymorphism 
(rs4072037) has been found to influence serum KL-6 levels in Caucasian and Japanese subjects, and may need to be considered in the calculation of normal upper limits and cut-off values [ 4,5].
Galecto Biotech AB Page 90of 105
GALACTIC -1 v7.1_UK 28 January 2022
References:
1.Ohshimo S, Yokoyama A, Hattori N, et al. KL -6, a human MUC1 mucin, promotes 
proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun 2005; 338: 
1845–1852.
2.Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL -6/MUC 1 in the clinical  
management of interstitial lung diseases. Respir Investig 2012; 50:3–13.
3.Satoh H, Kurishima K, Ishikawa H, et al. Increased levels of KL -6 and subsequent 
mortality in patients with interstitial lung diseases. J Intern Med 2006; 260:429–434.
4.Horimasu Y, Hattori N, Ishikawa N, et al. Different MUC1 gene polymorphisms in  
5.German and Japanese ethnicities affect serum KL -6 levels. Respir Med 2012; 106:1756 –
1764.
6.
Janssen R, Kruit A, Grutters JC, et al. The mucin -1 568 adenosine to guanine 
polymorphism influences serum Krebs von den Lungen -6 levels. Am J Respir Cell Mol 
Biol 2006; 34:496 –499.
PAI-1
Plasmin is a key protease involved in the repair of the damaged alveolar epithelium and the 
plasminogen activator inhibitor -1 (PAI -1) is the major inhibitor of plasminogen activators in 
plasma and the alveolar space. PAI -1 is one of the most important target genes in the TGF -
β/Smad signaling pathway, which can hinder the degradation of ECM composition and promote 
cell invasion and migration.  Multiple reports using preclinical models suggest that PAI-
1deficiency or inhibition of PAI-1activity attenuates fibrosis. [1]. Mice overexpressing PAI-1 
show increased bleomycin -induced lung fibrosis whilst mice deficient in PAI -1 show reduced 
fibrosis in this model [ 2,3].  PAI -1 has been shown to be elevated in the BALf in IPF patients 
compared to control [ 4,5].
Galecto Biotech AB Page 91of 105
GALACTIC -1 v7.1_UK 28 January 2022
References:
1.Flevaris P, Vaughan D. The Role of Plasminogen Activator Inhibitor Type -
1 in Fibrosis.
Semin Thromb Hemost. 2017 Mar;43(2):169-177.
2.Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH.
Bleomycin- induced pulmonary fibrosis in transgenic mice that either lack or overexpress 
the murine plasminogen activator inhibitor -1 gene. J Clin Invest. 1996 (1):232 -7.
3.Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, Simon RH, Drew AF.
Bleomycin- induced pulmonary fibrosis in fibr inogen -null mice. J Clin Invest. 2000 
Dec;106(11):1341-50.
4.Lison et al., 1999 Biomarkers : biochemical indicators of exposure, response, and 
susceptibility to chemicals 4, 361 -372.
5.Willems S, Verleden SE, Vanaudenaerde BM, Wynants M, Dooms C, Yserbyt J, So mers 
J, Verbeken EK, Verleden GM, Wuyts WA. Multiplex protein profiling of 
bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity 
pneumonitis. Ann Thorac Med. 2013 Jan;8(1):38- 45.
CCL18
CCL18 is a CC chemokine produced mainly by antigen -presenting cells including alveolar 
macrophages, and is elevated in BALf and serum in patients with IPF [1,2].CCL18 can stimulate 
pulmonary fibroblasts and increase collagen production in vitro [3]. In GB- HV-01 10 mg GB0139
treatment trended to reduce serum CCL -18 levels compared to the placebo group.
References:
1.CaiMBonella F, He X ,Sixt SU ,Sarria R, Guzman J ,Costabel U. CCL18 in serum, BAL 
fluid and alveolar macrophage culture supernatant in interstitial lung diseases. Respir 
Med. 2013 Sep;107(9):1444 -52.
Galecto Biotech AB Page 92of 105
GALACTIC -1 v7.1_UK 28 January 2022
2.Zhang Y
,Kaminski N .Biomarkers in idiopathic pulmonary fibrosis . Curr Opin Pulm 
Med. 2012 (5):441-6.
3.Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, 
Vollmer E, Müller -Quernheim J, Zissel G. A vicious circle o f alveolar macrophages and 
fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006 
(7):781 -92.
MCP -1
CC chemokines such as MCP -1 play important roles in the pathogenesis of 
interstitial lung diseases. Elevated CCchemokine levels have been observed in BALf of patients 
with IPF (reviewed in [1]). Elevated levels ofMCP -1 in BALf may be predictive of a poor outcome 
in patients with IPF [2].A deficiency in MCP -1 has been shown to protect mice from bleomycin-
induced lung fibrosis [ 2]. In the GB -HV -01 patient cohort there was a dose dependent trend for a 
reduction in plasma MCP -1 with GB0139 .  
References:
1.Osafo-Addo AD, Herzog EL. CCL2 and T cells in pulmonary fibrosis: an old player gets 
a new role. Thorax. 2017 (11):967-968.
2.Baran CP, Opalek JM, McMaken S, Newland CA, O'Brien JM Jr, Hunter MG, 
Bringardner BD, Monick MM, Brigstock DR, Stromberg PC, Hunninghak e GW, Marsh 
CB. Important roles for macrophage colony -stimulating factor, CC chemokine ligand 2, 
and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am J Respir Crit 
Care Med. 2007 Jul 1;176(1):78-89.
As well as the biomarkers described above there are several biomarkers of note which have shown 
to be elevated in IPF compared to control and have suggested prognostic significance for disease 
progression.  These include the Nordic collagen neo -epitopes ( Jenkins et al., 2015, Lance t. Respir 
Med. 3(6):462472) as well as epithelial markers SPD, SPA, KL-6, CA-125, CA-19) and matrix 
Galecto Biotech AB Page 93of 105
GALACTIC -1 v7.1_UK 28 January 2022
remodeling markers MMP7 and MMP1 (reviewed in Guiot et al., Lung. 2017 Jun;195(3):273 -280; 
Maher et al., 2017, Lancet Respir Med. (12):946 -955).  In additi on, we would like to incorporate 
the flexibility to measure new analytes as evidence for 
new biomarkers may evolve during the 
course of the study. 
Galecto Biotech AB Page 94 of 105
GALACTIC -1 v7.1_UK 28 January 2022
Appen dix 3. Definition of Acute Exacerbations in IPF
Acute respiratory worsening occurs in a small minorit y of patients with IPF annually 
(approximately 5 –10%) [ 1-3]. These episodes may occur secondary to common conditions such 
as pneumonia, pulmonary embolism, pneumothorax, or cardiac failure [ 4]. When a cause cannot 
be identified for the acute respiratory de cline, the term acute exacerbation of IPF has been used 
[3, 5-15]. It is presently unclear if acute exacerbation of IPF is simply a manifestation of an 
unidentified respiratory complication (such as pulmonary emboli, infection) contributing to an 
acute wor sening in a patient with IPF or represents an inherent acceleration in the 
pathobiological processes involved in IPF. 
Regarding the definition of AE in IPF, a revised "conceptual framework" was proposed by an 
international working group in 2016 [ 16].
The2007 proposed definition of an "acute exacerbation" (AE) of IPF included all of the 
following:
A previous or concurrent diagnosis of IPF
Deterioration within 30 days
New bilateral ground glass opacities and/or consolidation on a background of 
reticular or honeycomb pattern consistent with usual interstitial pneumonia (UIP)
No evidence of pulmonary infection by endotracheal aspiration or 
bronchoalveolar lavage
Exclusion of alternative causes including left heart failure, pulmonary embolism, 
or an identifiable cause of acute lung injury
The 2016 revised criteria more accurately reflect today's knowledge of AE -IPF and should allow 
for better insights into the etiology, treatment, and outcomes of this process [ 17]. Similar to the 
definition in 2007, this newly proposed framework defines an AE as " an acute, clinically 
significant respiratory deterioration characterized by evidence of new widespread alveolar 18.3
Galecto Biotech AB Page 95of 105
GALACTIC -1 v7.1_UK 28 January 2022
abnormality ," but does not set an exact 30 day limit for symptom onset and does not require 
exclusion of infection. The following diagnostic criteria are proposed:
A known diagnosis of IPF (diagnosis may be made at the time of acute respiratory 
deterioration)
Acute worsening, "typically less than one month's duration"
Computed tomography of the ches t with new bilateral ground glass opacification 
and/or consolidation superimposed on a background of findings consistent with 
usual interstitial pneumonia (bibasilar reticular opacities associated with 
honeycomb changes and traction bronchiectasis) 
Heart failure or fluid overload does not fully explain the worsening.
Based on our understanding that these events may be triggered similar to acute lung injury in the 
non-IPF patient population, events are further classified into "triggered" (ie, postprocedure, drug 
toxicity, infection, aspiration) versus "idiopathic" (ie, no inciting event identified). This new 
classification will allow for a more complete picture of these patients.
Pathophysiology and risk factors -While our current understanding of the patho physiology of 
AE-IPF is limited, AE has clinical similarities to acute respiratory distress syndrome (ARDS). 
Both have increased oxygen needs, bilateral ground glass opacities and/or consolidation on 
imaging, and histopathology demonstrating diffuse alveol ar damage [ 19-22]. It is known that 
there are multiple causes for ARDS and it is likely the same for those with AE -IPF. Further, IPF 
patients likely have maladaptive responses to lung injury, demonstrated by altered responses of 
IPF versus control fibrobla sts to stimuli in vitro [ 23, 
24]. 
There are multiple examples of lung injury that subsequently develop into an AE -IPF [ 25-28]. 
Microaspiration of gastric contents –Microaspiration of gastric contents is a 
proposed risk factor for exacerbations and progression of IPF, based on a meta -
analysis of clinical trials that demonstrated patients who received treatment for 
Galecto Biotech AB Page 96of 105
GALACTIC -1 v7.1_UK 28 January 2022
gastric reflux had slower decline of forced vital capacity (FVC), alt hough there 
was no difference in mortality [ 29].
Surgery and thoracic procedures –Thoracic procedures, such as surgical lung 
biopsy, lung cancer resection, and bronchoscopy, have been associated with the 
development of IPF exacerbations [30 -34]. Nonthorac ic surgical procedures have 
also been implicated in development of exacerbations [ 33]. Potential mechanisms 
include administration of high concentrations of oxygen and volutrauma or 
barotrauma during mechanical ventilation. However, a causal relationship 
between IPF exacerbations and procedures is difficult to ascertain due to the 
retrospective analysis of the studies. 
Advanced lung disease –Clinical factors of physiologically advanced IPF are 
associated with increased rates of AE, including: lower FVC, d iffusing capacity 
of the lung for carbon monoxide (DLCO), and six -minute walk distance [ 27, 
35, 
36]. 
Other –A number of other potential contributors have been implicated, such as 
evidence of pulmonary hypertension, higher body mass index, coronary artery
disease, and treatment with immunosuppressive therapy [ 36-38].
Clinical manifestations - In patients with IPF, an acute exacerbation typically presents with 
shortness of breath or worsening exercise tolerance that develop over days to weeks, but 
generally less than one month [ 17,39]. In a small series of 11 patients, the time from onset of 
symptoms to hospital admission averaged approximately 13 days [ 18]. Cough (with or without 
sputum production) is common; fever and flu -like symptoms may also be present.
On physical examination, the patient may be tachypneic and will typically have bibasilar 
crackles consistent with the underlying diagnosis of IPF.
Galecto Biotech AB Page 97of 105
GALACTIC -1 v7.1_UK 28 January 2022
Patients typically demonstrate impaired gas exchange, as evidenced by an arterial oxygen tension 
to fractio n of inspired oxygen ratio (PaO 2/FiO 2) of less than 225 mmHg or a decrease in the PaO 2 
of 10 mmHg or more from baseline.
High resolution computed tomography (HRCT) reveals bilateral ground glass or consolidative 
opacities superimposed on a background of typical HRCT features of IPF (eg, bibasilar reticular 
opacities, honeycomb changes, traction bronchiectasis).
Diagnosis -The diagnosis of AE -IPF is generally made in a patient with known or concurrently 
diagnosed IPF and the following featur es [17]:
An acute, clinically significant respiratory deterioration typically <1 month in 
duration
High resolution computed tomography (HRCT) demonstrating new bilateral 
ground glass opacification and/or consolidation superimposed on a background of 
findin gs consistent with usual interstitial pneumonia
Exclusion of heart failure and fluid overload as significant contributors to the 
deterioration
Flexible bronchoscopy with bronchoalveolar lavage (BAL) is used to identify infectious agents 
and exclude maligna ncy. While the 2007 criteria for AE
-IPF required the exclusion of infection, 
the 2016 criteria do not exclude potential triggers, such as infection, lung procedures/operations, 
drug toxicity, and aspiration [ 16, 17]. These potential triggers should be note d, but do not 
exclude AE -IPF.
DIFFERENTIAL DIAGNOSIS —The differential diagnosis of AE -IPF includes venous 
thromboembolism, infection, and heart failure. A pneumothorax can complicate IPF, but would 
usually be recognized on a conventional chest radiograph. Pulmonary hypertension developing 
as a consequence of IPF is also in the differential diagnosis of worsening dyspnea, but would not 
have the new radiographic opacities associated with AE- IPF.
Galecto Biotech AB Page 98of 105
GALACTIC -1 v7.1_UK 28 January 2022
Venous thromboembolism –IPF is associated with a significantl y increased risk 
of venous thromboembolism (VTE) [ 40-42]. The suspicion for VTE is increased 
in patients with obesity, immobilization, malignancy, and prior or family history 
of VTE. 
Infection –For patients who can tolerate the procedure, our standard pr actice is to 
perform a full investigation for potential lung infection and to initiate empiric 
antibiotics for pneumonia while studies are pending, as described. The choice of 
antibiotics for community -acquired pneumonia is described separately. 
Heart failure – Given the average age of individuals with IPF, careful cardiac 
assessment for heart failure or myocardial infarction is appropriate. We typically 
begin with serial troponin, brain natriuretic peptide (BNP), and an 
electrocardiogram. An echocardiogra m is not typically a first line assessment, but 
may be useful to evaluate for heart failure in a subset of patients, such as those 
with extrathoracic clinical features of heart failure or an elevated BNP. 
Pulmonary hypertension –Pulmonary hypertension (g roup 3), a well -known 
complication of IPF, also presents with worsening dyspnea, but without increased 
radiographic opacities. The diagnosis is often suspected in patients with 
worsening gas transfer without evidence of worsening interstitial lung disease.
Plasma BNP is often increased, and Doppler echocardiography can provide an 
estimate of pulmonary artery systolic pressure. A firm diagnosis requires right 
heart catheterization. 
References
1.King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, 
Leconte I, Roux S, Raghu G. BUILD -1: a randomized, placebo -controlled trial of 
bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75 –81.
Galecto Biotech AB Page 99of 105
GALACTIC -1 v7.1_UK 28 January 2022
2.Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd 
JE, Noth I, Olman MA, et al.; Idiopathic Pulmonary Fibrosis Clinical Research Network 
Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit 
Care Med 2007; 176:636–643.
3. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, 
Ohi M, et al. Double -blind, placebo -controlled trial of pirfenidone in patients with 
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040 –1047.
4.Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, 
Schwartz DA, Noble PW, Raghu G, et al.; IPF Study Group. The clinical course of 
patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963 –967.
5.Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings 
during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. 
AJR Am J Roentgenol 1997; 168:79 –83.
6.Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L, Poletti V. 
Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J
2003; 22:821–826.
7. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of 
idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J
2006; 27:143–150.
8. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation 
in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three 
cases. Chest 1993; 103:1808 –1812.
9. Kondoh Y, Taniguchi H, Yokoi T, Nishiyama O, Ohishi T, Kato T, Suzuki K, Suzuki R. 
Cyclophosphamide and low -dose prednisolone in idiopathic pulmonary fibrosis and 
fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005; 25:528 –533.
Galecto Biotech AB Page 100of 105
GALACTIC -1 v7.1_UK 28 January 2022
10.Kubo H, Nakay
ama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H. 
Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128:1475 –1482.
11.
Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients 
withacute exacerbation of idiopathi c pulmonary fibrosis undergoing surgical lung 
biopsy. Chest 2005; 128:3310 –3315.
12. Tiitto L, Bloigu R, Heiskanen U, Paakko P, Kinnula VL, Kaarteenaho- Wiik R. 
Relationship between histopathological features and the course of idiopathic pulmonary 
fibrosis/usual interstitial pneumonia. Thorax 2006; 61:1091 –1095.
13.Rice AJ, Wells AU, Bouros D, du Bois RM, Hansell DM, Polychronopoulos V, 
Vassilakis D, Kerr JR, Evans TW, Nicholson AG. Terminal diffuse alveolar damage in 
relation to interstitial pneumonias: an autopsy st udy. Am J Clin Pathol 2003; 119:709 –
714.
14.Churg A, Muller NL, Silva CIS, Wright JL. Acute exacerbation (acute lung injury of 
unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg 
Pathol 2007; 31:277 –284.
15.Kondo A, Saiki S. Acute exacerbation in idiopathic interstitial pneumonia (IIP). In: 
Harasawa M, Fukuchi Y, Morinari H, editors. Interstitial pneumonia of unknown 
etiology. Tokyo: University of Tokyo Press; 1989. pp. 33 –42.
16.Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary 
fibrosis. Am J Respir Crit Care Med 2007; 176:636.
17.Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary 
Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016; 
194:265.
18.Kim DS, Park JH, Park BK, et al. Acute ex acerbation of idiopathic pulmonary fibrosis: 
frequency and clinical features. Eur Respir J 2006; 27:143.
Galecto Biotech AB Page 101of 105
GALACTIC -1 v7.1_UK 28 January 2022
19.Ferguson ND, Frutos -Vivar F, Esteban A, et al. Acute respiratory distress syndrome: 
underrecognition by clinicians and diagnostic accuracy of three clin ical definitions. Crit 
Care Med 2005; 33:2228.
20.
Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic 
pulmonary fibrosis. Eur Respir J 2008; 32:170.
21.Oda K, Ishimoto H, Yamada S, et al. Autopsy analyses in acute exacerbation of
idiopathic pulmonary fibrosis. Respir Res 2014; 15:109.
22.Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with 
acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. 
Chest 2005; 128:3310.
23.Larsson O, Diebold D, Fan D, et al. Fibrotic myofibroblasts manifest genome -wide 
derangements of translational control. PLoS One 2008; 3:e3220.
24.Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a 
profibrotic positive feedback lo op. J Clin Invest 2014; 124:1622.
25.Johannson KA, Vittinghoff E, Lee K, et al. Acute exacerbation of idiopathic pulmonary 
fibrosis associated with air pollution exposure. Eur Respir J 2014; 43:1124. 
26.
Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation 
of idiopathic pulmonary fibrosis. Eur Respir J 2012; 39:352.
27.Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: 
incidence, risk factor s and outcome. Eur Respir J 2011; 37:356.
28.
Tomioka H, Sakurai T, Hashimoto K, Iwasaki H. Acute exacerbation of idiopathic 
pulmonary fibrosis: role of Chlamydophila pneumoniae infection. Respirology 2007; 
12:700.
Galecto Biotech AB Page 102of 105
GALACTIC -1 v7.1_UK 28 January 2022
29.
Lee JS, Collard HR, Anstrom KJ, et al. Anti- acid treatment and disease progression in 
idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. 
Lancet Respir Med 2013; 1:369.
30.
Hiwatari N, Shimura S, Takishima T, Shirato K. Bronchoalveolar lavage as a possible 
cause of a cute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med 
1994; 174:379.
31.
Bando M, Ohno S, Hosono T, et al. Risk of Acute Exacerbation After Video -assisted 
Thoracoscopic Lung Biopsy for Interstitial Lung Disease. J Bronchology Interv Pulm onol
2009; 16:229.
32.Bando T, Date H. [Surgical treatment of lung cancer in patients with pulmonary fibrosis. 
Kyobu Geka 2012; 65:714.
33.Ghatol A, Ruhl AP, Danoff SK. Exacerbations in idiopathic pulmonary fibrosis triggered 
by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the 
literature. Lung 2012; 190:373.
34.Sakamoto S, Homma S, Mun M, et al. Acute exacerbation of idiopathic interstiti al 
pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study. 
Intern Med 2011; 50:77.
35.Kondoh Y, Taniguchi H, Ebina M, et al. Risk factors for acute exacerbation of idiopathic 
pulmonary fibrosis --
Extended analysis of pirfenidone trial in Japan. Respir Investig
2015; 53:271.
36. Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic 
pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27:103.
37.Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerb ations and pulmonary 
hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012; 40:93.
Galecto Biotech AB Page 103of 105
GALACTIC -1 v7.1_UK 28 January 2022
38.Kakugawa T, Sakamoto N, Sato S, et al. Risk factors for an acute exacerbation of 
idiopathic pulmonary fibrosis. Respir Res 2016; 17:79.
39.Simon -Blancal V, Fr eynet O, Nunes H, et al. Acute exacerbation of idiopathic pulmonary 
fibrosis: outcome and prognostic factors. Respiration 2012; 83:28.
40.
Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary 
fibrosis and vascular disease: a popu lation -based study. Am J Respir Crit Care Med
2008; 178:1257.
41.Sode BF, Dahl M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of 
idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med 2010; 
181:1085.
42.Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated 
risk of thromboembolic disease. Eur Respir J 2012; 39:125.
Galecto Biotech AB Page 104of 105
GALACTIC -1 v7.1_UK 28 January 2022
19.0 A. RESPONSIBILITIES OF THE INVESTIGATOR
Clinical research studies sponsored by the sponsor are subject to ICH GCP and all the applicable 
local laws and regulations. The responsibilities imposed on investigators by the FDA are 
summarized in the “Statement of Investigator” (Form FDA 1572 
–A).
By signing the Form FDA 1572, the investigator agrees to assume the f ollowing responsibilities:
1.Conduct the study in accordance with the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that study related procedures, including study specific (non routine/non standard
panel) screening assessments are NOT performed on potential subjects, prior to the receipt of 
written approval from relevant governing bodies/authorities.
4. Ensure that all colleagues and employees assisting in the conduct of the study are informed 
of these obligations.
5. Secure prior approval of the study and any changes by an appropriate IRB/IEC that conform 
to 21 CFR Part 56 (for IND only), ICH, and local regulatory requirements.
6. Ensure that the IRB/IEC will be responsible for initial review, continuing rev iew, and 
approval of the protocol. Promptly report to the IRB/IEC all changes in research activity and 
all anticipated risks to subjects. Make at least yearly reports on the progress of the study to 
the IRB/IEC, and issue a final report within 3 months of study completion.
7.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50 (only for IND), 
ICH and local regulations, are met.
8. Obtain valid informed consent from each subject who participates in the study, and document 
the date of conse nt in the subject’s medical chart. Valid informed consent is the most current 
version approved by the IRB/IEC. Each informed consent form should contain a subject 
authorization section that describes the uses and disclosures of a subject’s personal 
informa tion (including personal health information) that will take place in connection with 
Galecto Biotech AB Page 105of 105
GALACTIC -1 v7.1_UK 28 January 2022
the study. If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each sub ject or the 
subject’s legally acceptable representative.
9.Prepare and maintain adequate case histories of all persons entered into the study, including 
eCRFs, hospital records, laboratory results, etc, and maintain these data for a minimum of 
2years follow ing notification by the sponsor that all investigations have been discontinued or 
that the regulatory authority has approved the marketing application. The investigator should 
contact and receive written approval from the sponsor before disposing of any su ch 
documents.
10.
Allow possible inspection and copying by the regulatory authority of GCP -specified essential 
documents.
11. Report adverse reactions to the sponsor promptly. In the event of an SAE, notify the sponsor 
within 24 hours.